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ABSTRACT
The population comprising older adults is growing exponentially, as are healthcare related costs.
Nearly $20 billion is annually expensed by older adults for health-related issues affiliated with
age-related decline in skeletal muscle mass. Yet, diagnostic criteria are not readily utilized in
clinical practice. PURPOSE: Therefore, the purpose of this study was to provide evidence for
use of blood biomarkers (myostatin, IGF-1) to predict appendicular skeletal muscle mass (ASM)
among middle-aged and older adults. METHODS: A cross-sectional study was conducted
among 106 individuals (n = 68 females; n = 38 males) aged ≥ 40 years of age (60.1 ± 11.1 y)
wherein blood biomarkers (serum myostatin and IGF-1) were examined relative to age and
appendicular skeletal muscle mass (ASM). Linear multiple regression analysis was used to
identify the model of best-fit to describe the relationship between the primary outcome variable
(ASM) and the set of biomarkers (myostatin, IGF-1). RESULTS: The results of the regression
model indicated 78% of the variance in ASM to be accounted for when utilizing the fourpredictor regression model, considering age, sex, serum myostatin and IGF-1. Neither biomarker
significantly contributed to the model and only accounted for <1.0% (myostatin) and 1.4% (IGF1) of the variance in ASM. CONCLUSIONS: Serum myostatin and IGF-1 concentrations were
not significant predictors of ASM among middle-aged and older adults. Results of the present
investigation add to meaningful conversation regarding the need for a preventative medicine
approach to sarcopenia diagnosis with age. Yet, further evaluation of key relationships amid all
sarcopenia-contributing variables, as they relate to blood biomarkers, serves as a starting point
for examining muscle mass status with age.
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CHAPTER ONE
INTRODUCTION
In the United States, there are 47.8 million older adults, accounting for 14.9% of the total
population (AOA, 2016; Bureau, 2015). By 2060, it is projected that the United States population
will be comprised of 98.2 million adults ≥ 65 years of age, 19.7 million of whom will be aged 85
years or older (Bureau, 2015). Within the past decade alone, the older adult population (≥ 60
years) has increased 34% (AOA, 2016). This exponential population growth places an increased
burden on the healthcare system. Older adults contribute more than $555 billion to healthcare
expenses, annually (CDC, 2013; Janssen, Shepard, Katzmarzyk, & Roubenoff, 2004). While
healthcare cost contributors are multifaceted, nearly $20 billion of these annual expenses are
directly linked to the age-related declines in skeletal muscle mass (Janssen et al., 2004;. Kim,
Cross, & Bamman, 2005). Termed sarcopenia, age-related skeletal muscle mass decline is one of
the major health problems amid the older population, affecting more than 24% of adults ≥ 65
years of age and 50% of adults ≥ 80 years of age (Baumgartner et al., 1998; Zembroń-Łacny,
Dziubek, Rogowski, Skorupka, & Dąbrowska, 2014). Sarcopenia results in: loss of muscular
strength, functional decline, decreased physical activity participation, and increased disability
(Baumgartner et al., 1998; Hulmi et al., 2009; Kim, Cross, & Bamman, 2005). Declines in
skeletal muscle mass and strength are limiting factors in late life physical independence (Morris
& Jacques, 2013). Thus, maintenance of sufficient skeletal muscle mass is essential for healthy
aging (Bonaldo & Sandri, 2013; Weaver, 2017).
Skeletal muscle mass serves as the primary reservoir for metabolically active tissue and is
imperative for healthy aging (Weaver, 2017), sustained muscular strength (Goodpaster et al.,
2006), functional capacity (Evans & Campbell, 1993), and the ability to perform activities of
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daily living (Janssen, Heymsfield, & Ross, 2002). After reaching its peak around the third decade
of life (Hurley, 1995; Janssen, Heymsfield, Wang, & Ross, 2000), skeletal muscle mass attrition
occurs at a rate of 1% per year after 20 years of age (Doherty, 2003). This decline in skeletal
muscle mass drastically accelerates after 50 years of age (Bautmans, Van Puyvelde, & Mets,
2009; Doherty, 2003; Hurley, 1995; Janssen et al., 2000), resulting in total muscle mass loss
upwards of 40% by 80 years of age (Rolland et al., 2008). While total-body skeletal muscle mass
loss is detrimental to the health of older adults, more importantly are the reductions in skeletal
muscle mass of the arms and legs, or appendicular skeletal mass (ASM) (Visser, Deeg, Lips,
Harris, & Bouter, 2000; Visser et al., 2002). Loss of ASM is attributed to reduced muscular
strength (Goodpaster et al., 2006), impaired functional capacity, and altered ability to perform
activities of daily living (Janssen et al., 2002)
An inherent consequence of skeletal muscle mass decline is the concomitant loss of
muscular strength. Significant strength losses occur beginning the fifth decade of life (Borst,
2004), reaching more than 4% per year after age 70 (Bautmans et al., 2009). These losses are
attributed to alterations in muscle fiber type and diameter (Kallman, Plato, & Tobin, 1990;
Larsson, Grimby, & Karlsson, 1979), greater occurrence of fibrous connective tissue within the
muscle (Frontera, Zayas, & Rodriguez, 2012; Kallman et al., 1990; Larsson et al., 1979),
abnormalities in neural and mechanical properties (Enoka, 1996; Lindle et al., 1997), and an
overall decline in skeletal muscle mass (Frontera, Hughes, Lutz, & Evans, 1991; Kallman et al.,
1990; Larsson et al., 1979). With muscle strength decline, follows difficulties in maintaining
physical function and mobility (Goodpaster et al., 2006), loss of independence into late-life
(Frontera et al., 2012; Goodpaster et al., 2006), and increased mortality (Manini & Clark, 2012).
Muscle strength declines are weakly associated with skeletal muscle mass loss (Manini & Clark,
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2012), but the necessity to maintain both is apparent for overall health (Bonaldo & Sandri, 2013)
and sustained quality of life and functional independence with age.
Alterations in physiological and biological function are also associated with sarcopenia;
such alterations include, but are not limited to, changes in hormone production and inhibited
protein storage (Fougère, Vellas, van Kan, & Cesari, 2015). Given these known changes, two
primary physiological factors of interest in sarcopenia mitigation are myostatin and insulin-like
growth factor-1 (IGF-1) due to the regulatory roles they play in protein synthesis. Myostatin, a
potent inhibitor of muscle growth, is overexpressed during periods of bedrest or prolonged
inactivity (Patel & Amthor, 2005) and is inversely correlated with skeletal muscle mass among
older adults (Schulte & Yarasheski, 2001). IGF-1, a growth hormone mediator, is an anabolic
signaling intermediate (Hunter, McCarthy, & Bamman, 2004) reduced with age, making it
difficult for skeletal muscle mass maintenance through late-life. Combined, increased myostatin
expression (Casperson, Sheffield-Moore, Hewlings, & Paddon-Jones, 2012; Kim, Cross, &
Bamman, 2005; Louis, Raue, Yang, Jemiolo, & Trappe, 2007; Schulte & Yarasheski, 2001;
Szulc et al., 2012; Yarasheski, Bhasin, Sinha-Hikim, Pak-Loduca, & Gonzalez-Cadavid, 2002)
and decreased IGF-1 signaling (Friedrich et al., 2008; Juul et al., 1994; Lin, Huang, & Lin, 2009)
result in accelerated muscle loss with progressing age.
Although sarcopenia is defined as the age-related loss of skeletal muscle mass, in order
for condition diagnosis, skeletal muscle mass decline must be accompanied with reduced
muscular strength (Cruz-Jentoft et al., 2010; Lauretani et al., 2003; Studenski et al., 2014) or
impaired physical mobility (Abellan Van Kan et al., 2009; Cruz-Jentoft et al., 2010; Studenski et
al., 2014). The most commonly used criteria for sarcopenia classification include appendicular
skeletal muscle mass, relative to body mass index (ASM BMI) (Studenski et al., 2014), combined
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with either reduced hand-grip strength (muscular strength assessment) or walking speed
(physical mobility assessment) (Cruz-Jentoft et al., 2010; Studenski et al., 2014). Although these
diagnostic criteria exist, they are not readily utilized in clinical settings; thus, detection of
sarcopenia in middle-aged and older adults is not common clinical practice. Instead, reductions
in skeletal muscle mass remain undetected until the occurrence of one or more adverse events.
Although blood profiles are often used in clinical settings to assess overall health status and
physiological organ function (e.g., liver, kidney, heart function, etc.) (ACSM, 2017), no such
assessments are currently used in assessing skeletal muscle mass. Myostatin and IGF-1 impact
skeletal muscle mass integrity and can easily be analyzed in serum but remain untested in
assessing skeletal muscle mass status across the lifespan. Therefore, the purpose of this study is
to provide evidence in support of the use of the aforementioned biomarkers to predict
appendicular skeletal muscle mass among middle-aged and older adults.

Research Hypothesis
Serum myostatin and IGF-1 will be significant predictors of lean mass status, as assessed
by appendicular skeletal muscle mass (ASM), among middle-aged and older adults.
a. Serum myostatin concentrations will positively correlate with age and negatively
correlate with appendicular skeletal muscle mass.
b. Serum IGF-1 concentrations will inversely correlate with age and positively
correlate with appendicular skeletal muscle mass.
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Operational Definitions
Aging, defined as an inevitable, time-progressive decline in physiological function
resulting in decreased fitness capacity and increased mortality rate (Fabian & Flatt, 2011; Flatt,
2012; Flatt & Schmidt, 2009; Partridge & Barton, 1996; Rose, 1991).
Middle-aged, defined as individuals aged 40-59 years.
Older adult, defined as individuals aged ≥ 60 years (Kim, Cross, & Bamman,
2005; Welle, Bhatt, Shah, & Thornton, 2002; Yarasheski et al., 2002).
Appendicular skeletal muscle mass (ASM), defined as the summation of total arm and
leg lean mass (Studenski et al., 2014). For purposes of this study, utilization of dual energy x-ray
absorptiometry measures for right and left arm and leg lean mass with be used as the summative
value ASM measure.
Appendicular skeletal muscle mass, adjusted for body mass index (ASMBMI), defined
as the summation of total arm and leg lean mass divided by calculated body mass index (BMI)
(Studenski et al., 2014)
Biomarker, defined as an objectively measured biological parameter providing
information on the mechanistic understanding of biological and pathogenic processes and
responses to pharmacologic therapeutic interventions (Calvani et al., 2015; Group, 2001). Ideally,
biomarkers will “support the diagnosis, facilitate the tracking of the condition of interest over
time, and assist healthcare professionals in clinical and therapeutic decision-making” (Cesari et
al., 2012).
Body mass index, as defined by the American College of Sports Medicine (ACSM,
2017) is an assessment of weight, in kilograms, relative to height, in meters squared (kg/m2).
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Dietary protein intake, defined as habitual dietary protein intake, as assessed via a 24hour dietary recall.
Low-protein intake, defined as 24-hour average habitual dietary protein intake
equating to less than the recommended dietary allowance for adults; < 0.8 grams per kilogram of
body weight per day (< 0.8 g⸱kg-1⸱d-1) (Institute of Medicine, 2005)
Moderate-protein intake, defined as 24-hour average habitual protein intake
equating to ≥ 0.8 g⸱kg-1⸱d-1 (Institute of Medicine, 2005) but ≤ 1.5 g⸱kg-1⸱d-1 (Ahmed & Haboubi,
2010; Fukagawa & Young, 1987; Wolfe, Miller, & Miller, 2008)
High-protein intake, defined as 24-hour average habitual protein intake equating
to > 1.5 g⸱kg-1⸱d-1 (Gorissen et al., 2017).
Muscular strength, defined as the amount of external force capable of being produced
by a specific muscle group or groups (ACSM, 2017). For the purposes of this study maximal
handgrip strength, defined as the “the maximum amount of isometric strength of the hand”
(Tieland, Verdijk, de Groot, & van Loon, 2015), will be used for muscular strength assessment.
Sarcopenia, of Greek etiology: ‘sarx,’ meaning flesh, and ‘penia,’ meaning loss
(Rosenberg, 1989; Rosenberg, 1997) is defined as the age-related decrease of skeletal muscle
mass. Sarcopenia classification is characterized by low lean mass status (male: ASM BMI < 0.789;
female: ASMBMI < 0.512) and a significant decrease in either muscular strength, as assessed by
handgrip strength (male: maximal handgrip strength < 26 kg; female: maximal handgrip strength
< 16 kg) (Studenski et al., 2014), or physical mobility, as assessed by habitual gait speed (< 0.8
m/s) (Cruz-Jentoft et al., 2010; Studenski et al., 2014). Severe sarcopenia classification is
characterized by low lean mass status and a significant decrease in both muscular strength and
muscular performance (Cruz-Jentoft et al., 2010; Studenski et al., 2014).
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Assumptions
1. It is assumed that participants will answer all questionnaires honestly.
2. It is assumed all participants will follow pre-testing guidelines and performance of study
parameters, as instructed.
Delimitations
1. Recruitment for this study will primarily take place in the Northwest Arkansas and
surrounding areas, convenience sampling presents as a potential limitation to
applicability of results to a larger sample population (Kallman et al., 1990) outside of this
region and/or of ethnic minorities.
2. Study pre-screening will entail participant completion of a detailed health history
questionnaire. As a result, all pre-screening data will be based on self-report. Researchers
will operate under the assumption that all responses to pre-screening questions are
answered honestly and openly. Individuals indicating certain prevalence of chronic
and/or acute conditions (e.g., liver or kidney failure of abnormalities; diagnosed type 2
diabetes) are liable to be excluded from the study based on self-report; however, no
baseline testing will be used to screen for such conditions.
3. This study is cross-sectional in design, providing for only a snapshot of the sample
population at one point in time (Levin, 2006). Although outcome variable (ASMBMI)
prevalence will be known, it will be difficult to make causal inferences since participants
will not be followed over an extended duration of time (Levin, 2006).
4. For the purposes of this study, only serum myostatin and IGF-1 will be utilized in the
assessment of sarcopenia status. While it is expected these biomarkers will capture a
large contribution of physiological changes present with sarcopenia, these biomarkers are
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not an all-encompassing representation of every biomarker potentially involved in the
pathogenesis of sarcopenia (Kalinkovich & Livshits, 2015). Further, these biomarkers are
only being examined in circulation. Therein lies the potential for different findings should
these biomarkers be measured at the tissue level (i.e., muscle biopsy).
Limitations
The limitation indicated below provides for an idea of those in which results of this study
may not be generalizable.

1. Given the specificity of the study, results may not be an accurate representation of
individuals with one or more co-morbid health conditions, individuals who have
experienced an acute ailment or injury resulting in hospitalization, or individuals
currently undergoing treatment for cancer or autoimmune related diseases.
Significance of Study
Sarcopenia is one of the major health problems negatively affecting the aging population.
Maintenance of sufficient skeletal muscle mass is essential for healthy aging, but reductions
often remain undetected due to lack of accessibility to body composition assessment tools.
Sarcopenia detection requires a reliable method of muscle mass determination, such as dual
energy x-ray absorptiometry (DXA) or computed tomography (CT); however, these types of
equipment are not readily available in clinics, nor are they commonly used to assess skeletal
muscle mass when such scans are performed (Cesari et al., 2012). Thus, there is a critical need
for the assessment of sarcopenia outside of traditional measures.
Blood profiles are commonly evaluated in clinical settings, providing useful information
on overall health and helping to potentially diagnose physical abnormalities (ACSM, 2017).
Several biomarkers have been linked to muscle protein synthesis, potentially providing insight
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on mechanisms for skeletal muscle mass accretion; nevertheless, use of biomarkers to assess
skeletal muscle mass has yet to be elucidated. Myostatin and IGF-1 are two physiological
elements of interest in sarcopenia development given their catabolic (myostatin) and anabolic
(IGF-1) signaling properties. With age, these biomarkers markedly fluctuate resulting in
accelerated muscle loss with progressing age. Despite understanding the inter-related effects of
aging and hormone signaling alteration on skeletal muscle mass, use of these biomarkers for
sarcopenia diagnosis is not current practice. Thus, an integrative approach identifying serum
biomarkers for use in the detection and prediction of muscle loss warrants further investigation.
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CHAPTER TWO
LITERATURE REVIEW

Aging is defined as a normal, progressive physiological deterioration taking place
throughout the adult period of life (Abrass, 1990) in absence of disease (Masoro, 2001);
however, as the population of older adults continues to increase, so does the occurrence of aging
in the presence of disease (Abrass, 1990). While many physiological functions are maintained
with age, subtle and irreversible changes in most organ systems occur by the third and fourth
decades of life (Boss & Seegmiller, 1981). Decrements are most commonly seen in organ
systems where homeostatic conditions are not maintained, such as skeletal muscle mass (Abrass,
1990). Maintenance of this homeostatic state becomes increasingly more challenging with age
and can be affected by multiple conditions, some of which include: fasting, exercise, physical
inactivity, and onset of disease (Sheffield-Moore & Urban, 2004).
Primarily used for movement, performance of physical activity and exercise, and serving
as a nutrient reservoir when the body is in a catabolic state (Bonaldo & Sandri, 2013), skeletal
muscle mass accounts for nearly 40% of total body weight and plays a complex role in human
body homeostasis (Argilés, Busquets, Stemmler, & López-Soriano, 2015). The delicate balance
between skeletal muscle protein breakdown and synthesis is an ongoing process that occurs with
growth, health, disease and aging (Sheffield-Moore & Urban, 2004). Of specific interest is the
affiliated decline in skeletal muscle mass with progressing age. This age-related skeletal muscle
mass decline is classically defined as sarcopenia (Rosenberg, 1989; Rosenberg, 1997). However,
with the evolution of sarcopenia studies, the definition of sarcopenia has become more allinclusive, outlining sarcopenia as an age-related decline in skeletal muscle mass accompanied by
simultaneous decrements in muscular strength and muscle function (Fulle, Belia, & Di Tano,
10

2005; Studenski et al., 2014). These declines negatively affect physical independence into late
life (Morris & Jacques, 2013), ultimately contributing to increased fall risk (Landi et al., 2012),
loss of independence (Yu, Khow, Jadczak, & Visvanathan, 2016), and mortality (Calvani et al.,
2015; Kim et al., 2014; Vetrano et al., 2014). Yet, preventative measures have not been
implemented to minimize sarcopenia onset.
Skeletal muscle dysfunction and rate of mass decline are age-dependent and largely
attributed to loss of motor units (Gutmann & Hanzlíková, 1973), decrements in muscle fiber
number, a shift in muscle fiber type, as well as atrophy of remaining muscle cells (Boss &
Seegmiller, 1981). Consequently, anabolic resistance develops resulting in alterations in protein
turnover, impaired hormone signaling, and decreased muscle regeneration capability (Argilés et
al., 2015). Given the multifactorial nature of sarcopenia, the pathophysiology of onset remains
complicated; endocrine dysfunction, increased inflammatory conditions, and alterations in
glucose, glycogen, and lipid metabolism are known contributors (Malafarina, Uriz-Otano,
Iniesta, & Gil-Guerrero, 2012; Pedersen & Febbraio, 2012). The magnitude of impact muscle
mass attrition and muscular strength decline have on aging adults is largely influenced by
alterations in modifiable lifestyle factors and physiological functioning (Carmeli, Coleman, &
Reznik, 2002), as outlined in Table 1 (Bautmans et al., 2009). These alterations are further
emphasized by inadequate nutrition and decreased performance of physical activity; ultimately
resulting in accelerated functional decline (Fulle et al., 2005; Roubenoff & Hughes, 2000) and
greater prevalence of disability (Hulmi et al., 2009; Kim, Cross, & Bamman, 2005). Thus,
maintenance of sufficient muscle mass is essential for healthy aging (Bonaldo & Sandri, 2013;
Weaver, 2017).
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Table 1
Physiological and Lifestyle Factors Contributing to Sarcopenia
Factor
Results
Physiological ↓ Hormone secretion and stimulation (growth hormone, IGF-1, testosterone,
oestrogen)
↓ Motor neurons, muscle fiber denervation
↓ Muscle tissue contractility ability
↑ Inflammatory markers (IL-6, TNF-α)
↓ Physical activity participation
↑ Increased immobilization as a result of bedrest or sedentary lifestyle
↓ Dietary intake (specifically, insufficient protein consumption)
↑ Inflammation due to life events (e.g. depression, disease, hospitalization)
Note: Table 1 is adapted from Table 2 in Bautmans, Van Puybelde, & Mets (2009), highlighting
the physiological (i.e., endogenous) and lifestyle (i.e., exogenous) factors contributing to
sarcopenia development.
Lifestyle

Sarcopenia diagnosis is problematic due to the multifactorial nature of the condition as
well as inadequate means for assessment. The status quo for sarcopenia diagnosis involves
assessing skeletal muscle mass. Dual energy x-ray absorptiometry (DXA) or computed
tomography (CT) scans are the most accurate and precise methods to assess skeletal muscle
mass, but accessibility to such assessments is limited and most scans are not conducted until age
65, when bone mineral density is evaluated (National Osteoporosis Foundation, 2017). Other
means for assessing skeletal muscle mass exist, but also have many limitations and/or are not
readily available in traditional clinical settings, as outlined in Table 2. Consequently, sarcopenia
often goes undetected until a person suffers a series of negative health consequences; it is
recommended to screen for sarcopenia only after suffering recurring falls, experiencing
unintentional weight loss, physical disability (i.e., cannot rise from a chair or bedridden)
(Fielding et al., 2011; Studenski et al., 2014; Yu et al., 2016) or significantly reduced muscular
strength (Studenski et al., 2014). Thus, specified means for detecting, diagnosing, and
classifying sarcopenia are further warranted.
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Table 2
Common Sarcopenia Assessment Methods
Technique
CT Scan
DXA scan
MRI Scan
BIA
Circumferences

Measurement
Muscle crosssectional area
Total skeletal
muscle mass
Muscle crosssectional area
Tissue
conductivity
Mid-arm and calf
circumference

Potential
Limitations/Comments
Radiation exposure;
expensive
Low radiation exposure;
reliable; expensive
Expensive; not readily
available
Reliability of measure(s)
questionable
Subcutaneous fat
influences measures

Applicable Setting for
Use
Clinical specialist and
Research
Clinical specialist and
research
Research
Clinical specialist and
research
Primary care and clinical
specialist

Note: Table 2 is adapted from Table 1 in Burton and Sumukadas (2010), highlighting different
techniques for measuring sarcopenia and Table 1 in Beaudart et al. (2016), outlining the
applicability of existing tools for sarcopenia assessment in research and clinical settings. CT =
computed tomography; DXA = dual energy x-ray absorptiometry; MRI = magnetic resonance
imaging; BIA = bioelectrical impedance analysis.
Sarcopenia classification
Sarcopenia classification has evolved from being solely dependent on examination of
skeletal muscle mass to a combination of skeletal muscle mass deterioration and functional
decline (Argilés et al., 2015). Various working groups have developed operational definitions of
sarcopenia using specified criteria for skeletal muscle mass, muscular strength, and muscle
function measures (Baumgartner et al., 1998; Chen et al., 2014; Cruz-Jentoft et al., 2010;
Fielding et al., 2011; Morley et al., 2011; Muscaritoli et al., 2010; Studenski et al., 2014).These
criteria are outlined in Table 3.
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Table 3
Sarcopenia Classification Working Definitions
Organization
Baumgartner et al., 1998
Muscaritoli et al., 2010

Cruz-Jentoft et al., 2010

ESPEN-SIG

European Working Group on
Sarcopenia in Older People
(EWGSOP)

Fielding et al., 2011

Morley et al., 2011

Studenski et al., 2014

International Working Group
on Sarcopenia (IWGS)
Society of Sarcopenia,
Cachexia and Wasting
Disorders

Foundation of NIH Sarcopenia
Project (FNIH)

Classification Criteria

Cutpoint (Men)

Cutpoint (Women)

ASM/ht2

<7.26

<5.45

Low muscle mass: % muscle mass

>2 SDs below mean in individuals aged 18-39y in
NHANES III cohort

4-minute walking speed test

<0.8 m/s

<0.8 m/s

1. Low muscle mass (ALM/ht2)

≤7.23 kg/m2

≤5.67 kg/m2

2. Low muscle strength (HGS)

<30 kg

<20 kg

3. Low physical performance (gait speed)
**Diagnosis based exhibiting criterion 1 and
(criterion 2 OR 3)

<0.8 m/s

<0.8 m/s

ALM/ht2

≤7.23 kg/m2

≤5.67 kg/m2

Gait speed

<1.0 m/s

<1.0 m/s

ALM/ht2

>2 SDs below mean in individuals aged 20-30y of
same ethnic group

Gait speed

≤1.0 m/s

≤1.0 m/s

6-minute walking distance

<400 m

<400 m

ALMBMI

<0.789

<0.512

Recommended: Grip strength (GSMAX)

<26 kg

<16 kg

Alternate: Grip strength adjusted for BMI
(GSMAXBMI)

<1.0

<0.56

Recommended: Appendicular lean body mass
adjusted for BMI (ALMBMI)

<0.789

<0.512

Alternate: ALM
Janssen et al., 2002

Skeletal Muscle Index (SMI)

<19.72 kg
<15.02 kg
Normal SMI: >1 SD above sex-specific mean of
young adult (18-39y; Sarcopenic SMI: ≥2 SDs
below sex-specific mean of young adult (18-39y)
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Note: Table 3 is adapted from Table 1 in Beaudart et al. (2014), highlighting the primary working definitions of sarcopenia
classification with respective cutpoints. ESPEN-SIG = European Society for Clinical Nutrition and Metabolism Special Interest
Groups; ALM = appendicular lean mass; ASM = appendicular skeletal muscle mass; BMI = body mass index; SMI = skeletal muscle
index.

Across all working groups, similarities exist in the use of ASM, also known as
appendicular lean mass (ALM), standardized for height, weight, or body mass index (BMI). This
is largely attributed to the associated decrements in muscular strength (Goodpaster et al., 2006),
functional capacity, and ability to sustain daily living (Janssen et al., 2002) found with
significant declines in ASM/ALM. For working groups utilizing muscular strength and/or muscle
function as classification criteria, handgrip strength and gait speed variables are consistent;
however, cutpoint criterion values vary. Albeit encouraging to have similarity in diagnostic
criteria, the variability between these indices provides for inconsistent sarcopenia classification.
Thus, further need is warranted for establishment of physiological parameter measures related to
skeletal muscle mass, muscular strength, and function.
Sarcopenia prevalence
It is well known that sarcopenia is a condition vastly affecting the aging population yet
means to ameliorate the condition remain limited and interventions not provided until after onset.
More than 24% of older adults (≥65 years) (Baumgartner et al., 1998; Zembroń-Łacny et al.,
2014) and 50% of individuals aged ≥80 years (Baumgartner et al., 1998; Zembroń-Łacny et al.,
2014) are affected by sarcopenia and the related deleterious health outcomes. Actual sarcopenia
prevalence remains a topic of debate due to diagnosis being heavily weighted upon the
inclusionary classification criteria as well as the age range in which sarcopenia criteria are
quantified.
As studies have progressed, indices for assessing sarcopenia have also evolved.
Transitioning away from the use of absolute skeletal muscle mass, or absolute skeletal muscle
mass converted to a percentage of total body mass (skeletal muscle index; SMI) (Janssen et al.,
2002), sarcopenia status quantification has moved toward the incorporation of skeletal muscle
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mass in combination with muscular strength and/or muscle function measures (Studenski et al.,
2014). Evidence to support the use of each of these indices for sarcopenia are outlined Table 3.
However, variability within these indices make for inconsistent classification. An example of this
vast variability is exhibited in an exploratory study out of our lab examining sarcopenia
classification among middle-aged and older adults based on skeletal muscle mass criteria. Data
were analyzed for 924 adults, ≥40 years of age. Individuals were classified as sarcopenic or nonsarcopenic using the following: absolute ASM, ASM relative to BMI (ASM BMI), ASMht2, and
SMI. Sarcopenia classification among middle-aged (40-59 years) men ranged from 0-93%,
depending upon skeletal muscle mass criteria: ASM (0%), ASMBMI (9%), ASMht2 (3%), and SMI
(93%). Sarcopenia classification among middle-aged women ranged from 6-86%, depending
upon classification criteria: ASM (25%), ASMBMI (6%), ASMht2 (23%), and SMI (86%). The >
60 y cohort consisted of 116 men (71.3 ± 7.3 y) and 211 women (69.3 ± 7.8 y). Of this cohort,
sarcopenia classification among older men ranged from 4-99%: ASM (4%), ASMBMI (43%),
ASMht2 (15%), and SMI (99%). Sarcopenia classification among older women ranged from 1390%: ASM (36%), ASMBMI (13%), ASMht2 (33%), and SMI (90%).
Results from this study highlight the vast variability that exists among skeletal muscle
mass assessment techniques for sarcopenia classification. While it is clear that sarcopenia is
more prevalent within the older cohort (≥60 years), evidence suggests sarcopenia is prevalent as
early as 40 years of age and speaks to the need for assessment of skeletal muscle mass decline
prior to age 60.
Clinical relevance
In spite of the abundant evidence supporting the importance of skeletal muscle mass
assessment across the lifespan, screening is not yet standard clinical practice. Significant
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reductions in skeletal muscle mass remain undetected due to lack of accessibility to muscle mass
assessment tools and/or inability to administer mobility or strength testing within a clinical
setting. Anthropometric measures, such as height and weight, serve as easy means for assessing
general health status and are easily utilized in clinical settings; however, they do not serve as
adequate means for the assessment and diagnosis of sarcopenia among older adults due to lack of
measurement validation (Beaudart, Rizzoli, Bruyère, Reginster, & Biver, 2014). DXA serves as
an accurate and precise method for assessment of skeletal muscle mass but is rarely used as such
in clinical settings (Cooper et al., 2013; Yu et al., 2016). Rather, sarcopenia risk often goes
unnoticed until a recurrence of negative health consequences are suffered by the patient (i.e.,
recurring falls, unintentional weight loss, physical disability, significantly reduced muscular
strength) (Fielding et al., 2011; Studenski et al., 2014; Yu et al., 2016).
Of common practice in clinical settings is the use of blood profiles for overall health
evaluation. In many instances, regular blood analysis is performed as a more definitive
assessment of total body physiological and organ functioning (i.e., cancer, diabetes, autoimmune
diseases, chronic kidney and/or liver disease) due to the normal aging process or implementation
of pharmacological intervention for stabilization of health-related condition (ACSM, 2017).
These fluctuations in biomarkers often occur before significant outward signs present (i.e.,
muscle loss); yet, biomarkers that contribute to maintaining muscle mass are not assessed on a
standard blood panel. Consequently, lack of screening limits the ability to prevent sarcopenia
onset and leaves only secondary and tertiary treatment as options for sarcopenia mitigation.
Despite advances in the evaluation of skeletal muscle mass, muscular strength, and
muscle function, it is understood that sarcopenia is a multi-mechanistic condition that has not yet
been fully characterized. Aside from lifestyle and natural aging processes, hormones play an
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influential role in skeletal muscle mass homeostasis and are ultimately responsible for protein
balance (Sheffield-Moore & Urban, 2004). In brief, skeletal muscle mass atrophy mitigation
largely depends on the ability to increase muscle protein synthesis. Of specific interest is
mammalian target of rapamycin (mTORC1) pathway activation, given its primary role in muscle
protein synthesis (Drummond, Dreyer, Fry, Glynn, & Rasmussen, 2009). Literature suggests
(Fernandes, Alves, Oliveira, Melo, & Soci, 2012; Greiwe, Kwon, McDaniel, & Semenkovich,
2001; Hulmi et al., 2009; Reidy & Rasmussen, 2016; Rolland et al., 2008; Sandri, 2008)
upstream mTORC pathway activation is regulated by amino acid consumption, muscle
contraction (i.e., resistance exercise; RE), and anabolic signaling intermediates.
Two intermediates of interest in sarcopenia mitigation are myostatin and IGF-1 given
their catabolic (myostatin) and anabolic (IGF-1) signaling properties. These biomarker properties
play an influential role in upstream mTORC1 pathway activation and, ultimately, regulation of
skeletal muscle mass integrity. Myostatin and IGF-1 are easily analyzed in serum; however, the
clinical relevance of each in sarcopenia detection and classification remains unknown. Therefore,
the purpose of this review is to delve further into the multi-faceted roles myostatin and IGF-1
play in the regulation of skeletal muscle mass throughout the lifespan. Due to the typical age of
onset for physiological and physical decline, all variables (myostatin and IGF-1) will be explored
for a population of men and women aged ≥ 40 years, to the extent to which the literature
provides evidence.
mTORC1 pathway overview
The mTORC1 pathway is a central regulator of cellular growth integrating both
intracellular and extracellular signals for metabolism and promotion of protein synthesis (BarPeled & Sabatini, 2014; Laplante & Sabatini, 2009). Growth factors, energy status, oxygen, and
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amino acids are all signaling agents responsible for mTORC1 pathway regulation (Laplante &
Sabatini, 2009). Growth factors, such as IGF-1, “stimulate mTORC1 through the activation of
insulin and Ras signaling pathways” whereas “amino acids represent a strong signal that
positively regulates mTORC1” with leucine being an essential amino acid needed for pathway
activation (Laplante & Sabatini, 2009). Myostatin, an anabolic inhibitor, has been found to block
IGF-1 and the IGF1/PI3K/AKT pathway (Rodriguez et al., 2014), a pathway which aids in
activating mTORC1. In lieu, the FOXO1 pathway, and related transcription factors, can be
turned on resulting in enhanced muscle atrophy (Rodriguez et al., 2014). Amino acid intake and
resistance exercise have been found to mitigate muscle atrophy, and may be due to metabolic
pathway signaling. Unfortunately, with age, the responses to amino acid intake and resistance
exercise implementation may be impaired resulting in altered or attenuated upstream activation
of the mTORC1 pathway and unfavorable conditions for muscle mass accretion (Francaux et al.,
2016). Thus, examination of upstream pathway regulators as they relate to skeletal muscle mass
modulation among middle-aged and older adults warrants further investigation.
Myostatin overview
Myostatin, also known as growth differentiation factor 8 (Roth & Walsh, 2004; L. Whittemore et
al., 2003), is a member of the transforming growth factor-β (TGF-β) superfamily of secreted proteins in
the body. As a member of the TGF-β superfamily, myostatin is a prominent muscle-specific

hormone that plays a critical role in the regulation of skeletal muscle mass (Huang, Chen, &
Chen, 2011; McPherron, Lawler, & Lee, 1997). Unique to TGF-β superfamily, myostatin
expression is exclusively restricted to skeletal muscle (Whittemore et al., 2003) and is found in
circulation in the blood. In serum and skeletal muscle, myostatin exhibits a diverse binding
potential and can be found bound to several proteins responsible for modulation of activation
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(Joulia-Ekaza & Cabello, 2007). Myostatin primarily presents as a potent anabolic inhibitor of
skeletal muscle growth and development (Hittel et al., 2010; Joulia-Ekaza & Cabello, 2007;
Szulc et al., 2012; Whittemore et al., 2003) that is prevalent in higher concentrations during periods of
bedrest or prolonged inactivity (Patel & Amthor, 2005) and lower concentrations in states of

muscle hypertrophy. However, due to myostatin’s association with multiple proteins responsible
for stimulation and inhibition of its action, understanding the regulation of this growth factor
complex (Sheffield-Moore & Urban, 2004).
Numerous instances of myostatin downregulation have shown to increase muscle mass in
animal models (Joulia-Ekaza & Cabello, 2007). Identification of this role was first recognized
and most extensively studied in cattle (Huang et al., 2011; McPherron et al., 1997), sheep
(Huang et al., 2011), and mice (Amthor et al., 2007; Huang et al., 2011); the presence of double
muscling of cattle and sheep breeds presenting as a result of myostatin gene mutation and
downregulation (Huang et al., 2011). Conversely, clinical studies performed on humans have
established a correlation between serum myostatin concentrations and muscle atrophy;
specifically, increases in myostatin expression are prevalent in individuals experiencing atrophy
as a result of HIV infection (Gonzalez-Cadavid et al., 1998), cachexia, prolonged bed rest,
disuse, and muscle wasting in older men and women (Joulia-Ekaza & Cabello, 2007; Yarasheski
et al., 2002). As such, myostatin presents as a potential mediating biomarker involved in skeletal
muscle wasting and sarcopenia.
Myostatin and age. Skeletal muscle mass is largely maintained via molecular alterations
in protein synthesis and degradation. With age, these processes are impaired, making for less
efficient protein synthesis and greater vulnerability to detrimental hormonal responses. It is well
known that myostatin increases with age (Schulte & Yarasheski, 2001; Szulc et al., 2012;
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Yarasheski et al., 2002). The variability in myostatin concentration differs across age cohorts,
with the lowest concentrations of myostatin generally seen in younger adults (18-35 years)
(Lakshman et al., 2009; Schulte & Yarasheski, 2001; Yarasheski et al., 2002) and the greatest
concentrations in older cohorts (>60 years) (Yarasheski et al., 2002). The magnitude of
difference in myostatin concentration between young (19-35 years), middle-aged (60-75 years),
and old (76-92 years) adults is significant. Specifically, older men (60-75 years) have 22-40%
greater myostatin concentration as compared to their 20-35-year-old counterparts. Findings are
similar in comparing older women (60-75 years) with younger women (19-35 years); older
women exhibit a 32.5-42% greater myostatin concentration than their younger counterparts
(Kim, Cross & Bamman, 2005; Yarasheski et al., 2002).
While this does not hold true for all observations (Kim, Cross, & Bamman, 2005;
Lakshman et al., 2009; Roth et al., 2003; Welle et al., 2002), most reports do indicate myostatin
concentration to increase with age (Kim, Corss, & Bamman, 2005; Yarasheski et al., 2002).
Unfortunately, due to the inconsistency in reporting of myostatin concentration values and the
variability in assessing myostatin concentration, in-depth analysis of the magnitude of change in
myostatin with progressing age is difficult to discern. General relationships with myostatin and
age provide a solid foundation for further investigation of this association in the present study.
Myostatin and muscle mass. Given the potent catabolic role of myostatin signaling in
protein synthesis and growth, myostatin presents as an acceptable biomarker for assessing
skeletal muscle mass. However, establishment of a clear relationship of myostatin concentration
and muscle mass proves difficult given the variability in body composition assessment
modalities as well as the influence of disease state(s). The most prominent skeletal muscle mass
assessments in the literature include anthropometric-related (i.e., height, weight, body mass
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index) and tissue-specific measures (i.e., skeletal muscle mass, total body mass, fat free mass).
Previous studies indicate muscle and plasma myostatin protein concentrations increase with body
mass among lean and extremely obese individuals (Hittel et al., 2010; Hittel, Berggren, Shearer,
Boyle, & Houmard, 2009). Similarly, studies performed in clinical populations indicate increases
in myostatin concentration are exhibited under conditions of muscle atrophy (e.g., cancer
cachexia, HIV infection, disuse, etc.) (Gonzalez-Cadavid et al., 1998). In non-diseased states, a
correlation between elevated myostatin concentration and muscle loss exists (Whittemore et al.,
2003), but this does not always hold true for older adults. In older cohorts, weak insignificant
correlations (R2 = .01, p = .42) are present when analyzing serum myostatin with lean body mass
(Lakshman et al., 2009). Clear delineation of the relationship myostatin concentration has on
muscle mass has been difficult to discern due to methodological variation across studies.
However, plausible indicated discrepancies may be attributed to the significant differences in
total body mass, fat-free mass, and muscle mass among men and women throughout the lifespan
(Yarasheski et al., 2002).
A better understanding of the interactive effects of muscle wasting with age, in relation to
changes in myostatin, is highlighted by Yarasheski and colleagues (2002). The examination of
myostatin in correlation with a fat-free mass index (fat-free mass/height2) and muscle mass index
(muscle mass/height2) indicates myostatin concentrations are inversely correlated with fat-free
mass index (r = -.48, p < .0001) and muscle mass index (r = -.94, p = .017) (Schulte &
Yarasheski, 2001). While the magnitude of difference in myostatin concentration is agedependent, with younger cohorts having significantly greatly concentrations, those with the most
compromised body composition show the greatest alterations. Frail elderly women (76-92 years)
display the largest change in myostatin concentration as compared to their non-frail old (60-72
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years; 24.5%) and young counterparts (19-35 years; 65%) (Yarasheski et al., 2002). Taken
together, these findings suggest reduced lean tissue mass is associated with higher myostatin
concentration.
Similar findings to that of Yarasheski and colleagues (2002) are presented in individuals
of diseased states where muscle atrophy is present. Gonzalez-Cadavid et al. (1998) demonstrate
this in their investigation of myostatin expression correlates between healthy and HIV-infected
men (19-65 years). Results from this study indicate serum myostatin inversely correlates with
fat-free mass among both healthy and HIV-infected men (r = -.30, p = .007). In comparing
myostatin with a fat-free mass index and body mass index, inverse correlations were also
revealed (r = -.30, p = .003 and r = -.30, p = .02, respectively). Regarding the state of muscle
wasting among the HIV-infected men, the degree of muscle wasting and overall weight loss were
impactful on the myostatin to muscle mass relationship. Specifically, HIV-infected men that had
not experienced significant weight loss still had myostatin concentrations approximately 22%
greater than those of their healthy male counterparts. Similarly, HIV-infected individuals
experiencing more than 10% weight loss had 20% greater myostatin concentrations than their
HIV-infected counterparts who had remained weight stable. This suggests weight and lean mass
to play an influential role in disease regulation and myostatin concentration.
Resembling HIV, COPD is a chronic condition that results in skeletal muscle wasting and
significantly elevated myostatin concentrations (Ju & Chen, 2012). In older COPD patients (6073 years), myostatin concentration elevations in excess of 37.5% exist, as compared to agematched healthy male counterparts (Ju & Chen, 2012). However, when stratified for sex
myostatin inversely correlates with skeletal muscle mass (R2 = .2, p < .0001) and body mass
index (R2 = .084, p = .019) in men only. Taken together, these data are suggestive of the
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catabolic properties of myostatin and the integral role it may play in the regulation of muscle
mass among older adults and individuals of muscle-related diseased states.
In contrast to the aforementioned studies, some investigations indicate myostatin is not
correlated with lean body mass. Comparisons between young (18-35 years) and old (60-75 years)
men indicate no significant correlation of myostatin with lean body mass (Lakshman et al.,
2009). Similar findings were present in comparing 20-30 year-old males and females to older
(65-75 years) men and women; no significant relationships were observed between myostatin
expression and body mass for either cohort despite differences in weight, body fat percentage,
and muscle volume (Roth et al., 2003). Reasons postulated for the lack of difference found
between the aforementioned cohorts were not clearly articulated but may be due to
methodological variation in sample preparation and/or body composition modalities (e.g., DXA,
MRI, underwater weighing, algorithmic calculations).
Myostatin and sarcopenia. Taken together, all aforementioned data provide evidence of
the critical role myostatin plays in the pathophysiology of muscle protein wasting in diseased
states, as compared to a healthy population. It is evident that conflicting models exist in
examination of the relationship of myostatin with age-induced sarcopenia. Some studies suggest
myostatin concentration does not increase with age, but might actually be lower than younger
cohorts (Lakshman et al., 2009). Much of the variability in such reports are partly due to the
modality of measure, the timing of the biological sample collection used for analysis, and
additional external influences (e.g., physical activity, comorbid disease, etc.). Despite these
conflicted findings, the basic mechanism for myostatin function in skeletal muscle hypertrophy
and protein synthesis is well understood. Inhibition of myostatin among older adults presents as
an effective means for deterring skeletal muscle mass atrophy with progressing age while
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simultaneously improving overall physical function and health (White & LeBrasseur, 2014).
Means for myostatin inhibition provides promising evidence that early detection of elevated
levels will allow for implementation of therapeutic interventions to assist with the reversal
process (Whittemore et al., 2003). Given this understanding, further work is warranted
examining the clinically beneficial roles of endogenous myostatin regulation among middle-aged
and older adults for the earlier detection, and mitigation, of age-related muscle atrophy (Huang et
al., 2011).
IGF-1 overview
In many instances, growth factors are important for the evaluation of growth and
maturation. Aging affects many physiological and regulatory functions. These alterations often
take place at the hormonal level and can vastly impact homeostatic bodily function. Similar to
myostatin, IGF-1 plays a key role in muscle development and growth. As a growth-related
peptide, IGF-1 production is largely dependent upon growth hormone secretion. Primarily
produced in and secreted from the liver, IGF-1 can also be found in circulation bound to many
cell types given its diverse receptor binding capacity (Brisson & Barton, 2013). However, the
age-related decline in growth hormone production (Clemmons, 2012) results in a synergistic
decline in systemic and local IGF-1 production (Harris et al., 1997; Payette et al., 2003).
Consequently, therein lies an impairment in the metabolic homeostasis needed for activation of
the anabolic signaling pathway needed for protein synthesis, tissue growth (Clemmons, 2012),
and overall muscle mass maintenance (Sharples et al., 2015). This is particularly important
among middle aged (40-59 years) and older adults (≥60 years) given IGF-1 is an upstream
mTORC1 pathway regulator. Decrements in IGF-1 secretion are significantly increased with age,
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making it harder for muscle mass accretion (Hiroyuki Yamamoto, Motoi Sohmiya, Nobuyuki
Oka, & Yuzuru Kato, 1991).
In addition to age (Juul et al., 1994), prominent age-dependent alterations in IGF-1
circulation can be attributed to fluctuations in sex hormone production (Clemmons, 2012;
Cuttler, Vliet, Conte, Kaplan, & Grumbach, 1985; Hiroyuki Yamamoto et al., 1991), nutrient
status and overall dietary intake (Merimee, Zapf, & Froesch, 1982; Hiroyuki Yamamoto et al.,
1991), impaired liver function (Clemmons, 2012), and changes in the sensitivity of cells to the
growth factor itself (Ruiz-Torres & Soares de Melo Kirzner, 2002). The slowing of cell
sensitivity to growth factors, with progressing age, is largely problematic among older adults due
to the heavy influence growth factors and cell signaling play on maintaining whole-body
homeostasis (Abrass, 1990; Clemmons, 2012). Consequently, more than 30% of older adults
have circulating levels of IGF-1 below the normal range found in younger cohorts (Papadakis et
al., 1995; Perrini et al., 2010).
Although establishing normative serum IGF-1 concentration values has proven difficult
due to the high variability in assay analysis procedures (Chanson et al., 2016), relatively high
concentrations of circulating IGF-1 have been associated with lower mortality risk (Brugts et al.,
2008). In comparison, lower IGF-1 concentrations have been associated with poor knee extensor
muscle strength, impaired walking ability and decreased walking speed, as well as impaired
overall mobility (Barbieri et al., 2003; Cappola, Bandeen-Roche, Wand, Volpato, & Fried,
2001). Taken together, the versatile role IGF-1 plays in overall health status into late life
suggests decrements in IGF-1 concentration may be a point of interest in combatting various
health conditions among older adults (Junnila, List, Berryman, Murrey, & Kopchick, 2013)
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IGF-1 and age. Circulating IGF-1 concentrations significantly differ across age cohorts.
Early, and continuing works of serum IGF-1 examination indicate concentrations to gradually
increase from birth through adolescence before declining in adulthood (Harris et al., 1997; Juul
et al., 1994; Sharples et al., 2015). Irrespective of sex, IGF-1 concentrations negatively correlate
with age (Hofmann et al., 2015; Juul et al., 1994; Lin et al., 2009; Rosario, 2010; Yamamoto,
Sohmiya, Oka, & Kato, 1991) and are significantly higher among younger age cohorts (≤50
years), as compared to older age cohorts (>50 years) (Benbassat, Maki, & Unterman, 1997;
Brabant & Wallaschofski, 2007; Hofmann et al., 2015; Lin et al., 2009; Rosario, 2010;
Yamamoto et al., 1991). Evidence of this progressive decline is exhibited among a number of
studies outlined in Table 4, with the most significant declines seen among individuals aged ≥60
years (Junnila et al., 2013).
An early study highlighting the progressive decline in IGF-1 was performed by Juul et al.
(1994), in which blood samples taken from 1030 healthy children, adolescents, and adults were
analyzed for assessment of variation in serum IGF-1 concentrations. Results indicated prepubertal children to experience gradual increases in IGF-1, with a steeper increase during
pubertal (adolescent) years. Following puberty, a subsequent significant decline in IGF-1
concentration was seen into late life (80 years). Specifically, among adults aged 20-80 years,
serum IGF-1 concentrations were shown to negatively correlate with age (r = -.71) and
significantly declined (p < .0001) back toward pre-pubertal levels in late-life. These results are
similar to results of a prior study conducted by Yamamoto and colleagues (1991) examining the
distribution of IGF-1 concentrations among men and women aged 21-80 years. Among these age
cohorts (21-40 years and 41-80 years), IGF-1 concentrations significantly declined with age and
served as a negative correlate with age for middle-aged (r = -.54, p < .005) and elderly females (r
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= -.31, p < .01), as well as middle-aged and elderly males (r = -.48, p < .005) (H. Yamamoto et
al., 1991). Later studies exploring the relationship of IGF-1 concentrations with age are
consistent with the findings of Yamamoto et al. (1991) and Juul et al. (1994), indicating IGF-1
concentrations among men and women aged 36-70 years to significantly decline (p < .01) and
negatively correlate with progressing age (r = -.51) (Lin et al., 2009); the same holds true for
elderly women 65-92 years of age (ρ = -.36, p < .01) (Hofmann et al., 2015).
Although IGF-1 concentration decline is consistent with progressive age, the magnitude
of decline may be indicative of a more telling story. Rates of IGF-1 concentration decline vary
from decade to decade; the most prominent declines seen take place among adults ≥ 60 years of
age, but occur among adults as young as 40 years of age. Among healthy men and women aged
40-49 years, declines in IGF-1 range from 16-46% when compared to their younger 20-39-yearold counterparts (Brabant et al., 2003; Chanson et al., 2016; Rosario, 2010; Yamamoto et al.,
1991). This magnitude of decline is similar (10-31%) when examining IGF-1 concentration
among older adults (60-69 years) as compared to their middle-aged counterparts (40-59 years)
(Benbassat et al., 1997; Brabant et al., 2003; Chanson et al., 2016; Lin et al., 2009; Rosario,
2010; Yamamoto et al., 1991). Among individuals aged ≥70 years, an additional 3-30% IGF-1
concentration decline takes place, as compared to their 60-69-year-old counterparts (Brabant et
al., 2003; Chanson et al., 2016; Friedrich et al., 2008; Lin et al., 2009; Rosario, 2010; Yamamoto
et al., 1991). This magnitude of change is telling for clinical implications suggesting biochemical
alterations taking place at the cellular level may contribute to outward deleterious effects, such as
declines in muscular strength and functional ability due to skeletal muscle mass loss with age.
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Table 4
IGF-1 Concentration across Age Cohorts
Population (M/F)
Yamamoto et al., 1991

N = 207 (103/104)

Measure
plasma IGF-1

Age
Cohort
(y)
21-30

IGF-1 (μg/l)

31-40

Men
252.4 ± 45.2
232.5 ± 74.2

Women
332.6 ± 63.9
229.6 ± 100.6

41-50
51-60
61-70

231.5 ± 59.6
185.5 ± 76.0
160.7 ± 36.7

199.0 ± 68.1
192.4 ± 66.0
146.8± 65.9

71-80

151.2 ± 44.8

142.8 ± 62.1

Papadakis et al., 1995

N = 104

plasma IGF-1

75.5 ± 4.9

134.7 ± 43.6

Benbassat et al., 1997

N = 66

serum IGF-1

20-39
63-81
20-29
30-39
40-49

234 ± 14
154 ± 8
230-299
174-194
156-163

209-273
165-179
150-157

50-59
60-69
70-80
52-92
20-39

139-148
118-129
101-108
155.6 ± 64.3
144-215

127-140
97-112
82-85
139.1 ± 51.6
152-216

40-59
60-64
65-74
>74
≤50

118-143
119
104-118
107
362.4 ± 108.4
327.7 ± 66.9

121-135
119
98-109
97
446.6 ± 126.0
307.6 ± 105.7

Brabant et al., 2003

Payette et al., 2003
Friedrich et al., 2008*

Lin et al., 2009

N = 558 (232/326)

N = 60 (35/25)

serum IGF-1

serum IGF-1

>50
Rosario 2010

N = 1,000 (500/500)

serum IGF-1

Chanson et al., 2016

N = 899 (463/436)

serum IGF-1

21-40
41-60
61-75
76-85
18-39

105-345
78-263
61-210
52-174
115-430

118-487

40-59
60-89

88-261
71-237

82-296
60-208

Note: *indicates median values reported
IGF-1 and muscle mass. Given the anabolic role of IGF-1 hormone signaling in protein
synthesis and tissue growth, IGF-1 presents as an acceptable biomarker for assessing muscle
mass status. However, establishment of a clear relationship between IGF-1 concentration and
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muscle mass proves difficult due to the variability of body composition measures presented
within the literature as well as the heavy influence age and nutrition status have on IGF-1
concentration. The most prominent measures of body composition in the literature, relative to
IGF-1 concentration, include anthropometric-based metrics (i.e., body mass index; waist-to-hip
ratio; height) and various tissue-specific metrics (e.g. total body fat; soft-tissue lean mass;
muscle mass). Generally speaking, in younger populations (<20 years), IGF-1 concentrations
best correlate with anthropometric-based metrics (Juul et al., 1994) whereas in older populations,
IGF-1 does not consistently correlate with anthropometric or tissue-specific metrics (Brugts et
al., 2008; Harris et al., 1997; Payette et al., 2003; Vestergaard et al., 2014). Further, in states of
extreme nutrient deprivation or metabolic catabolism (e.g., anorexia nervosa, cancer cachexia),
IGF-1 concentrations are markedly lower (Brabant & Wallaschofski, 2007; Caregaro et al.,
2001), but significantly correlate with body mass index (r = .64, p < .001), fat mass (r = .57, p <
.001), and muscle mass (r = .66, p < .001) (Caregaro et al., 2001). Conversely, in states of
nutrient overload and heightened anabolism, such as in obese populations, IGF-1 concentration is
generally elevated (Brabant & Wallaschofski, 2007; Gianotti et al., 1998; Veldhuis &
Iranmanesh, 1996). Although these relationships are generally apparent, there appears to be an
age-dependent discrepancy across measures making for unclear delineation of the relationship
between IGF-1 and muscle mass.
Among pre-pubertal children, linear regression analysis reveals serum IGF-1 is positively
correlated with anthropometric-based measures, such as body mass index (r = .44, p < .0001) and
height (r = .88) (Juul et al., 1994). This similarity also exists among young (19-23 years) male
collegiate athletes, in which IGF-1 only correlates with height after adjusting for age (β = 3.5 ±
1.7, p = .041) (Han, Huang, Chen, & Yang, 2017). Although meaningful, these associations do
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not translate into adulthood and late life nor do they shed light on the relationship of IGF-1
concentration and tissue-specific measures of lean mass within younger and older individuals.
Relative to younger cohorts, body mass index is known to positively correlate with lean
mass among older adults (Abbasi et al., 1998; Schneider et al., 2006). Data reported in the
DETECT study (Schneider et al., 2006) suggests IGF-1 to have a biphasic relationship to body
mass index (Brabant & Wallaschofski, 2007); body mass index values between 20 and 35 kg/m2
being associated with greater IGF-1 values, and body mass index values less than 20 or greater
than 35 kg/m2 being associated with a lower concentration of IGF-1 (Brabant & Wallaschofski,
2007; Schneider et al., 2006). Taken together, these relationships predict body mass index to
only add about 1% to the explained variance in IGF-1 concentration among the total sample
population and up to 7% of the explained variance in the obese groups (Schneider et al., 2006).
Other anthropometric-based measures used to examine the relationships with IGF-1
include waist-to-hip ratio. Utilization of waist-to-hip ratio measures to examine the relationship
with IGF-1 suggest sex-dependent differences exist (Abbasi et al., 1998). Specifically, in
women, skeletal muscle mass significantly correlates with waist-to-hip ratio (r = .30, p < .01),
but not IGF-1 (r = -.01). The opposite holds true for men; skeletal muscle mass significantly
correlates with IGF-1 (r = .32, p < .0001), but not with waist-to-hip ratio (r = .15). While these
relationships are important, not all studies reveal correlations of IGF-1 concentration with
anthropometric-based measures among men and women aged 20-70 years (Vestergaard et al.,
2014), suggesting a greater need for tissue-specific comparisons for deeper insight on the
influential role IGF-1 plays in skeletal muscle mass atrophy with age.
Exploration of IGF-1 concentration in relation to tissue-specific body composition
measures hold similar discrepancies to that of anthropometric-based metrics. Early works
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conducted among older adults (72-94 years old) indicate IGF-1 concentration is not associated
with total body fat (p = .83), body fat per kilogram of body weight (p = .50), lean mass (p = .84),
lean mass standardized to body weight (p = .44), or lower extremity lean mass (p = .77) in men
(Harris et al., 1997). Women, however, exhibited slightly different associations; a significant
relationship was found with IGF-1 concentration and lean mass (p = .001), but not in relation to
total body fat (p = .07), body fat per kilogram of body weight (p = .23), soft-tissue lean mass
standardized to body weight (p = .21), or lower extremity lean mass (p = .11) (Harris et al.,
1997). Additional studies indicate total body fat positively correlates with IGF-1 among men (r =
.43, p < .001), but not among women (Vestergaard et al., 2014). Despite the slight sex-dependent
variability in the indicated relationships of IGF-1 with body composition and skeletal muscle
mass, evidence suggests IGF-1 plays an influential role in muscle mass modulation with age.
In short, anthropometric measures appear most related to IGF-1 concentration among
younger cohorts and a combination of anthropometric and tissue-specific measures most related
to IGF-1 concentration among older cohorts. Inconsistent correlations are prominent in the
literature, but significant positive associations with muscle mass have been reported
(Baumgartner, Waters, Gallagher, Morley, & Garry, 1999). Greater concentrations of IGF-1 have
been predictive of smaller fat-free mass losses among men over time (Payette et al., 2003);
however, these findings are not consistent among older women. This lack of congruency in
associations is attributed to the drastic decline in IGF-1 among women following 50 years of age
(Payette et al., 2003). Despite these sex- and age-specific discrepancies, low IGF-1
concentrations have been associated with lower levels of lean mass (Harris et al., 1997), and
higher IGF-1 concentrations indicative of smaller decrements of lean mass loss with progressing
age (Payette et al., 2003), suggesting a certain sarcopenia protective effect of IGF-1 with age.
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Thus, there is a need for greater understanding of the true relationship of IGF-1 concentration
with skeletal muscle mass for the purpose of sarcopenia prediction, diagnosis and the tracking of
muscle mass status over time (Cesari et al., 2012)
IGF-1 and sarcopenia. IGF-1 plays an important role in the prevention of muscle
atrophy (Clemmons, 2009). However, with progressing age, cell function declines and causes
alterations in the anabolic potential of IGF-1 as a growth mediator. Reductions in IGF-1
concentration are associated with marked declines in skeletal muscle mass and function with age
(Sharples et al., 2015). Among sarcopenic individuals, there is an approximate 33% decline in
circulating IGF-1 (Benbassat et al., 1997; Sharples et al., 2015). Contributors to this decline
include progressive age, altered nutrition, and physical inactivity and can result in detrimental
alterations in grip strength, lower extremity strength, and overall physical function (Papadakis et
al., 1995). Ample evidence suggests declines in this anabolic hormone occur well before 60
years of age, yet monitoring of the change in concentration, in relation to muscle mass, is not
standard clinical practice. Consequently, a clear understanding of the pathophysiology of IGF-1
regulation with skeletal muscle mass decline remains to be elucidated. Further investigation is
warranted establishing the central role IGF-1 plays in human aging and disease, as well as its
predictive capacity for sarcopenia diagnosis.
Conclusion
Sarcopenia is one of the major health problems negatively affecting the aging population.
Maintenance of sufficient skeletal muscle mass is essential for healthy aging, but reductions
often remain undetected due to lack of accessibility to body composition assessment tools.
Sarcopenia detection requires a reliable method of skeletal muscle mass determination, such as
DXA or CT; however, these types of equipment are not readily available in clinics, nor are they
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commonly used to assess skeletal muscle mass when such scans are performed (Cesari et al.,
2012). Thus, there is a critical need for the assessment of sarcopenia outside of traditional
measures.
Blood profiles are commonly evaluated in clinical settings, providing useful information
on overall health and helping to explain physical abnormalities (ACSM, 2017). Serum myostatin
and IGF-1 have been linked to skeletal muscle mass, potentially providing insight on
mechanisms for skeletal muscle mass accretion; nevertheless, use of these biomarkers to assess
skeletal muscle mass has yet to be elucidated. With age, these biomarkers markedly fluctuate and
are related to accelerated muscle loss with progressing age. Despite understanding the interrelated effects of aging and hormone signaling alteration on skeletal muscle mass regulation, use
of these biomarkers for sarcopenia detection is not current practice. Thus, an integrative
approach identifying serum biomarkers to be used for the detection and prediction of sarcopenia
warrants further investigation. Therefore, the purpose of this study is to provide evidence
supporting the use of serum myostatin and IGF-1 in predicting sarcopenia status among middleaged and older adults.
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CHAPTER THREE
METHODOLOGY

The present investigation was aimed at: (1) correlating blood biomarkers (serum
myostatin and IGF-1) with age and appendicular skeletal muscle mass (ASM) and (2) developing
a sarcopenia prediction model utilizing these biomarkers (myostatin, IGF-1).
Study design
This study was cross-sectional design wherein blood biomarkers (serum myostatin and
IGF-1) were examined relative to age, lean mass status (ASM), and functional ability (handgrip
strength; gait speed). Linear multiple regression analysis was used to identify the model of bestfit to describe the relationship between the primary outcome variable (total appendicular skeletal
mass) and the set of biomarkers (myostatin, IGF-1). Desired project sample size was 100
participants, based on typical sample size from previous works utilizing logistic regression
(Long, 1997). All individuals were analyzed as a single cohort and then stratified based on sex
(male; female), age group (40-59 y; ≥ 60 y), and appendicular skeletal muscle mass. Given the
magnitude of the sample size, participant recruitment was targeted throughout study progression
to ensure adequate distribution of men and women among each age cohort; targeted recruitment
entailed specifically screening participants based on health history and age. Use of this design
allowed for timely data collection (Levin, 2006) and permitted for the achievement of
appendicular skeletal muscle mass prediction model development.
Participants
Men and women ≥ 40 years of age were recruited for participation in the present
investigation. Participants were recruited from the Northwest Arkansas and surrounding areas via
the following strategies: University of Arkansas Newswire – study advertisement was placed in
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the electronic newsletter reaching all individuals with a University e-mail address; Butterfield
Trail Retirement Community – combined efforts with the Fitness & Wellness Programs
Coordinator allowed for access to 400 residents and the placement of study flyers in resident
mailboxes; Osher Lifelong Learning Institute – provided access to a minimum of 30 individuals
via an educational presentation; Senior Activity & Wellness Centers – several centers, within a
20-mile radius of the University, were visited and flyers distributed; and heavy reliance was
placed on word-of-mouth from former research participants.
In addition to meeting age criteria, individuals interested in study participation underwent
a detailed pre-screening process. Pre-screening entailed completion of a detailed health history
questionnaire (HHQ; Appendix A) with follow-up questions from the primary researcher to
ensure eligibility. Study enrollment was dependent upon the following HHQ inclusionary
criteria: no unstable or unmanaged (meaning diagnosed, but not treated or medically supervised)
cardiovascular disease or hypertension; no current or previous (within past year) type 2 diabetes
diagnosis; no current or previous (within past year) diagnosis of renal or hepatic abnormalities or
diseases; no current or previously diagnosed (within past year) cancer; no neuromuscular or
musculoskeletal disease or injury prohibiting participation in functional task performance or
activities of daily living (ADLs; bathing, grooming, dressing, eating, toileting,
ambulating/transferring). Individuals having reported any of the aforementioned conditions on
their HHQ were deemed ineligible for study participation due to the significant impact these
parameters may have on blood immunohistochemistry and/or the safety of assessment
performance by the participant. Individuals meeting baseline criteria were provided informed
consent and scheduled a single testing appointment at the Exercise Science Research Center
(ESRC). Signing of the informed consent (Appendix B) served as clearance for conducting all

36

tests outlined in the procedures sections and indicated participant understanding of all protocols,
potential risks, and benefits involved in study participation. At this appointment, all assessments
were then completed.
Procedures
In brief, study conduction steps were comprised of the following: recruitment; prescreening; providing informed consent; at-home assessment completion; and one appointment at
the ESRC for cognitive and body composition assessment, completion of a 24-hour dietary
recall, blood draw, and performance of functional tasks.
Following pre-screening, qualifying individuals scheduled a 1.0-1.5-hour testing
appointment that took place in the ESRC. Prior to this appointment, participants were provided
instructions for completion of the Community Health Activities Model Program for Seniors
(CHAMPS) questionnaire (Appendix C) for the assessment of physical activity participation
(Stewart et al., 2001). Participants also received pre-testing guidelines to be followed the day
prior to their scheduled testing appointment. In brief, pre-testing guidelines emphasized:
refraining from consumption of caffeine, alcohol, and any other foods/beverages 8-10 hours prior
to their testing appointment; consuming only water throughout the 8-10 hour fast and the
morning of testing; maintaining a regular eating and hydration pattern the day prior to testing;
and, refraining from exercise (especially strenuous) the day prior to testing. All pre-testing
guidelines were set to minimize external influence on blood biomarker fluctuation; a complete
list of guidelines can be found in Appendix D.
Participants reported to the ESRC for their testing appointment, following an 8-10-hour
fast and remained fasted until blood draw completion. Upon arrival, all at-home materials were
reviewed by a trained researcher to ensure all necessary information was reported and the
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CHAMPS completed in its entirety. All participants then reported their dietary intake, including
all foods and beverages consumed the day prior to their testing appointment. Guidelines for this
assessment are provided in Appendix E. Individuals, aged 65 and older, then completed baseline
cognitive testing via mini-mental state examination (MMSE; Appendix F) administration by a
trained researcher; individuals scoring ≤ 16/30 were considered cognitively impaired (Can et al.,
2017; Folstein, Folstein, & McHugh, 1975) and ineligible to move forward with further study
participation. Individuals scoring ≥17/30 on the MMSE were considered cognitively able to
provide consent and proceeded with further assessments. Anthropometric measures (height,
weight) were taken, body mass index (BMI) calculated, and body composition assessed via dual
energy x-ray absorptiometry (DXA). Venipuncture was completed prior to the conduction of all
subsequent assessments. Two vials of venous blood were drawn (maximum of 12 mL) via
standard venipuncture procedures and serum used for analysis of myostatin and IGF-1. To allow
for adequate serum separation, blood samples sat at room temperature for 30-60 minutes before
being centrifuged at 4℃ for 15 minutes at a speed of 1000 x g. Serum was immediately aliquoted
and transferred to 1.5 mL disposable, conical-bottom micro tubes (VWR, Hanover, Germany) for
storage at -80°C until analysis. Serum concentrations of myostatin and IGF-1 were quantified
using enzyme linked immunosorbent assay (ELISA) kits, according to the manufacturer’s
protocols (R & D Systems, Minneapolis, MN). Following blood draw, participants were
permitted to eat and/or drink before the completion of the following functional tasks: muscular
strength, via handgrip dynamometry, and functional mobility via gait speed (habitual- and fastpaced 10-meter walk). At the completion of all assessments within the laboratory testing
appointment, participants were considered to have successfully completed study participation.
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Specific details regarding each component of the pre-screening and testing sessions are
outlined below. This protocol is approved by the Institutional Review Board at the University of
Arkansas (Protocol No: 1709049984; Appendix G).
Instrumentation
Detailed health history questionnaire. All interested participants were required to
complete a detailed health history questionnaire prior to study enrollment. Given many health
parameters, past and present, influence blood chemistry and overall functional quality of life, the
health history questionnaire was designed as a screening tool and inquired about pertinent healthrelated items. The sections comprising the health history questionnaire consisted of: present
health status, past medical history, family history, and medications and supplements being taken
(prescribed and over-the-counter). An example detailed health history questionnaire is provided
in Appendix A.
Community Health Activities Model Program for Seniors (CHAMPS) activities
questionnaire for older adults. This instrument was originally designed to evaluate
interventions for increasing physical activity among older adults (Stewart et al., 2001); however,
for the purposes of this study, the questionnaire was administered to evaluate physical activity
level among middle-aged and older adults. This 41-item paper and pencil questionnaire was
designed to provide outcome measures for various physical activity parameters while also taking
into consideration social engagements (Stewart et al., 2001). CHAMPS was completed
electronically by all participants prior to arrival for their respective testing appointment. Upon
arrival, a trained researcher reviewed the completed CHAMPS activities questionnaire to ensure
all components were properly completed. If a participant failed to complete the questionnaire
prior to appointment arrival, materials were provided for the participant to complete the survey
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on-site. Data collected from this questionnaire were reported in total caloric expenditure, per
week, for exercise-related activities. A copy of the CHAMPS questionnaire, including all
instructions, is provided in Appendix C. Test-retest reliability estimates, based on 6-month
stability for physical activity have been reported (Hekler et al., 2012) for low-light activity (> 1
and ≤ 2 METs; ICC = .70), high-light activity (> 2 and < 3 METs; ICC = .68), moderate to
vigorous activity (≥ 3 METs; ICC = .66), and total meaningful activity (≥ 2 MET; ICC = .69).
Test-retest reliability estimates for caloric expenditure from moderate to vigorous physical
activity (ICC = 0.61) and caloric expenditure from total meaningful activity (ICC = .64) are also
reported (Hekler et al., 2012).
Dietary recall. Because the blood biomarkers assessed in the present study are sensitive
to nutrient intake, a 24-hour dietary recall was conducted at each participant’s respective testing
appointment in order to establish baseline macronutrient status. This afforded for the opportunity
to asses any potential influential factors on biomarker concentration based on nutrient intake. To
ensure participants fully understood what needed to be included in their dietary recall, detailed
instructions were provided by a trained researcher and the 24-hour recall conducted in an
interview-type format. In brief, all participants were instructed to recite all food items and
beverages (including water) consumed over the course of the prior day, including as much detail
as possible and/or food label information, when possible. To assist with this process, a trained
researcher thoroughly interviewed each participant and asked follow-up questions regarding the
record content (i.e., brands of food, food quantity, intake time, etc.) when applicable. All dietary
record information was then entered into Nutritionist Pro (Axxya Systems, 2007) software for
macronutrient intake analysis. Detailed instructions and sample data collection sheet are included
Appendix E.
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Mini-mental state exam (MMSE). The MMSE was administered to all qualifying
individuals to ensure all participants were cognitively aware of what they were agreeing to
participate in (informed consent) and understood all study parameters. This validated, 30-item
cognitive assessment was broken down into two main parts: part one was used to assess
orientation, memory and attention; part two was used to assess one’s ability to name and follow
written and verbal commands, write a spontaneous sentence, and re-create a complex polygon
(Cockrell & Folstein, 2002; Folstein et al., 1975). Upon arrival for the testing appointment, a
trained researcher administered the MMSE to each qualifying participant in a quiet, distraction
free room. Individuals scoring ≥ 17/30 were considered to have non-severe cognitive impairment
and deemed eligible for study participation (Can et al., 2017; Folstein et al., 1975). Individuals
scoring ≤ 16/30 were considered to have severe cognitive impairment and were not eligible for
study participation. A copy of the MMSE, including administration instructions, is provided in
Appendix F. MMSE exhibits high validity for verbal IQ (r = .78) and performance IQ (r = .66),
and has high 24-hour test-retest reliability (r = .83) (Folstein et al., 1975).
Anthropometric and body composition measures. Height and weight were measured
using a Detecto Physician’s Scale (Webb City, MO) and values recorded to the nearest 0.1 cm
and 0.1 kg, respectively. Body mass index (BMI) was calculated as a ratio, utilizing height and
weight measures (weight in kilograms/height in meters squared).
Dual energy x-ray absorptiometry (DXA) (GE, Medical Systems, Madison, WI) was used
to assess body composition, including lean mass and fat mass. One total body scan was
performed per participant. Prior to conducting the DXA scan, participants were asked to remove
any removable form of metal from their bodies (i.e., clothing with metal zippers, snaps, buttons;
jewelry; hearing aids; glasses; etc.) as well as their shoes and any other extraneous items that
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would influence overall scan results. Participant anthropometric and demographic information
were entered into the DXA analysis software (Lunar Prodigy enCORE™ 2008, version 12.20,
GE Healthcare Systems, Wauwatosa, WI) and participants again informed of the DXA
procedures, risks, and benefits. Standard laboratory DXA protocols were utilized for all scans.
Briefly, each participant was positioned on the scanner table using the following procedure: lying
supine and centered along the midline indicator on scanner table, fitting within the confines of all
indicated parameters or adjusted for adequate total body estimate; hands flat with palms down;
arms alongside the body; and head 3 cm below horizontal line table mark nearest crown of skull.
Velcro straps were placed around the knees and ankles of each participant to assist in limiting
movement during scan. Following participant positioning on table, a summation of instructions
were again given, and the participant asked to lie as still as possible, with eyes closed, for the
entire duration of the scan; scan duration was body thickness dependent and ranged from 6-11
minutes for completion. All scans were conducted and analyzed by the same investigator to
control for inter-researcher variability. Results from each scan were used for participant
stratification by age and lean mass status (ASMBMI) to ensure an adequate total sample size
among age cohorts (40-59 y; ≥ 60y). Lean mass stratification entailed participant classification as
sarcopenic or non-sarcopenic, as defined by the FNIH (ASMBMI < 0.512 = sarcopenic female;
ASMBMI < 0.789 = sarcopenic male) (Gray, Glenn, & Binns, 2016; Studenski et al., 2014).
Venipuncture. Each participant underwent venous blood draw in the fasted state.
Participants endured a single stick blood draw utilizing a 21-gauge needle blood collection set
with tubing, multi-luer adapter, and pre-attached holder (BD Vacutainer® Safety-Lok Blood
Collection Set with Pre-Attached Holder, Franklin Lakes, NJ; Supplier No: 368652; Cat No:
89005-534). A maximum of 12 mL (two small vials; 6 mL each) of blood was collected in serum
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blood collection tubes (BD Vacutainer® Venous Blood Collection Tubes, clot activator serum
tubes, 13 x 100 mm, Franklin Lakes, NJ; Supplier No: 368660; Cat No: 95026-688). The blood
sampling procedure (i.e., venipuncture) and subsequent blood analyses were approved by the
Institutional Biosafety Committee (IBC protocol #13021). The blood drawn during this project
was solely used for measuring serum myostatin and IGF-1 concentrations.
Blood samples. Blood samples were collected in serum separator tubes and left to clot in
a thermoneutral environment for 30-60 minutes prior to centrifugation. Upon clotting, collected
samples were centrifuged for at 4°C for 15 minutes at 1000 x g. Serum was immediately
transferred to 1.5 mL disposable, conical-bottom micro tubes (VWR, Hanover, Germany; Cat
No: 89000-028) for aliquot storage at -80°C until analysis.
Serum concentrations of myostatin and IGF-1 were quantified using enzyme linked
immunosorbent assay (ELISA) kits according to the manufacturer’s protocols (R & D Systems,
Minneapolis, MN); specific details per assay are indicated below. In brief, all reagents (i.e., wash
buffers, pretreatments, substrate solutions, standards) and serum samples were brought to room
temperature. All microplates were prepared with standards, controls, and/or serum samples such
that all standards and samples were measured in duplicate, allowing for 40 samples to be run per
microplate set-up. At the completion of each protocol, stop solution was added following the
designated incubation periods, allowing for cessation of the peroxidase/TMB
(tetramethylbenzidine) reaction. The color change intensity, following the addition of the stop
solution, was indicative of the magnitude of the presence of the analyte being assessed.
Serum myostatin ELISA. Serum myostatin analysis was conducted per the
manufacturer’s protocol for the GDF-8/Myostatin Quantikine ELISA Kit (R & D Systems,
Minneapolis, MN; Cat No: DGDF80). Aforementioned steps for sample preparation and running
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of assay were carried out and sample optical density measured using a BioTek Synergy™ HT
plate reader (Bio Tek Instruments, Highland Park, Winooski, VT, 2006) set to 450 nm against
540 nm, as a reference. Data were linearized by plotting the log of the GDF-8 concentrations
versus the log of the optical density and the best fit line determined by four-parametric
regression analysis. Total analysis run time, including set-up and conduction of procedures, was
estimated at 6.0 hours per assay. Detailed assay procedures and data analysis techniques are
outlined Appendix H.
Serum IGF-1 ELISA. Serum IGF-1 analysis was conducted per manufacturer’s
protocols for the Human IGF-1 Immunoassay Quantikine ELISA Kit (R & D Systems,
Minneapolis, MN; Cat No: DG100). Aforementioned steps for sample preparation and running
of assay were carried out and sample optical density measured using a BioTek Synergy™ HT
plate reader (Bio Tek Instruments, Highland Park, Winooski, VT, 2006) set to 450 nm against
540 nm, as a reference. Duplicate readings were averaged, and the average zero standard optical
density subtracted. Data were linearized by plotting the log of human IGF-1 concentrations
versus the log of the optical density on a linear scale, and the best fit line determined by
regression analysis. Total analysis run time, including set-up and conduction of procedures, was
estimated at 6.0 hours per assay. Detailed assay procedures and data analysis techniques are
outlined in Appendix I.
Muscular strength assessment. Handgrip strength served as the muscular strength
measure (Lauretani et al., 2003) and was assessed using a digital Takei grip-strength
dynamometer (Takei Scientific Instruments, Niigata City, Japan); test-retest reliability for
handgrip strength has been previously recorded (ICC = .95) (Bohannon & Schaubert, 2005).
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For assessment administration, a trained researcher first fit the handgrip dynamometer to the
hand of each participant, ensuring proper fit by confirming a 90° angle was maintained at the
interphalangeal joint of the index finger. Once set to best fit, the participant was provided a
familiarization trial on each hand. The familiarization trial consisted of the participant holding
the handgrip dynamometer and gripping as forcefully as possible, once with each hand.
Following familiarization, a total of three trials were completed on each hand. For each trial, the
participant was instructed to assume an upright, standing position with arms relaxed by their
sides, wrists in a neutral position with palms facing their legs. Once in the proper position and
dynamometer fitting comfortably in hand, the participant was asked to squeeze the dynamometer
as forcefully as possible until the researcher said, “Stop.” The researcher then recorded the value
on the respective data collection sheet, started a timer, and proceeded with the same processes on
the opposing hand. This continued for a total of three trials on each hand, with a 1-minute rest
period between trials on each hand. All recorded values were denoted on the data collection sheet
and the strongest indicated grip strengths on each hand used for analyses.
Sarcopenia classification/stratification. For potential sample stratification, all participants
were classified for sarcopenic status following the completion of all study assessments.
Sarcopenia was defined according to the operational definition set forth by the Foundation for
the National Institutes of Health (FNIH) Sarcopenia Project (Studenski et al., 2014). The primary
measure utilized for determining sarcopenic status was ALM BMI. Supplemental measures
contributing to sarcopenic status classification included maximal handgrip strength and gait
speed. Sarcopenic classification cut-points/reference values are outlined in Table 5.
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Table 5
Recommended Cut-Points/Reference Values for Sarcopenia Identification
Cut-point
Men
Women
HGSmax (kg)
< 26.00
< 16.00
ALMBMI
< 0.789
< 0.512
GS (m/s)
< 0.8 m/s
< 0.8 m/s
Note: HGSmax = maximal handgrip strength, measured in kilograms; ALMBMI = appendicular
lean mass adjusted for body mass index (BMI), expressed as a ratio value; GS = gait speed,
measured in meters per second. Table contents are adapted from Cruz-Jentoft et al. (2010),
Studenski et al. (2014), and Van Kan et al. (2009).
Gait speed assessment. Gait speed was assessed based on the time it took for each
participant to walk a total of 10 meters at their habitual walking speed as well as a brisk walking
speed. This measure (10-m walk) served as a reliable (Adell, Wehmohorner, & Rydwik, 2013)
and valid (Peters, Fritz, & Krotish, 2013) functional fitness assessment for community-dwelling
older adults; reliability for habitual walking speed being 0.93 (Peters et al., 2013) and test-retest
reliability being 0.86 for maximal walking speed (Adell et al., 2013).
For this assessment, participants were instructed to walk from one cone to the other under
two different conditions, habitual walking speed and as quickly and safely as possible. One cone
was placed at the start (0-meter mark) and another placed at the stopping point (20-meter mark).
One set of TC-PhotoGates (PhotoGates A & B) was placed 5-meters from the starting cone and
the second set of TC- PhotoGates (PhotoGates A & B) placed at the 15-meter mark. This set-up
permitted for a 5-meter acceleration period, 10-meter gait speed snapshot, and 5-meter
deceleration. To ensure accurate measures of habitual and fast gait speed, participants were
asked to perform each walking condition fully, from cone to cone. Time to complete each trial
was recoded utilizing the TC-Timer and all gait speed values recorded to the nearest .1 second. A
total of one practice bout and two recorded trial bouts were performed for each walking
condition (habitual and brisk paces). A rest range of 30-60 seconds was provided between each
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bout to allow for participant recovery. The average of the habitual walking speeds and the brisk
walking speeds were taken and denoted as the final score, respective to walking condition. Gait
speed, per walking condition, was calculated as distance walked divided by time (gait speed =
distance, in meters / time, in seconds). An example walking course set-up is highlighted in
Appendix J.
Statistical analysis
Data were analyzed using SPSS statistical analysis software (IBM SPSS Statistics,
Version 25). Boxplot analyses were used to identify outliers and outlying data points omitted
from analyses. Descriptive measures were reported as means and standard deviation (mean ± SD)
and an independent samples t-test performed to identify sex-specific differences among
variables. Sarcopenia status was defined as ASMBMI of < 0.789 or < 0.512 for men and women,
respectively, and meeting one of the two functional criteria (hand-grip < 26 kg or < 16 kg for
men and women, respectively or gait speed < 0.8m/s) (Studenski et al., 2014). Initial correlation
analyses were conducted to identify significant relationships between serological measures
(myostatin and IGF-1), muscle mass (ASM), and age cohort. Multiple regression analysis was
conducted utilizing standard statistical analysis software (IBM SPSS Statistics, Version 25) for
the identification of a model of best-fit to describe the relationship between the primary outcome
variable (ASM) and the set of independent variables (myostatin, IGF-1). Additional one way
ANOVA analyses were conducted to identify significant sex-specific differences between age
cohorts (40-49 y; 50-59 y; 60-69 y; ≥ 70 y) on all variables of interest. Bonferonni post-hoc
analyses were conducted for variables of significance to identify where cohort differences
existed among sexes. Statistical significance for correlation, regression, and ANOVA analyses
was set at α = .05.
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CHAPTER FOUR
RESULTS
The purpose of this study was to provide evidence in support of the use of blood
biomarkers (serum myostatin and serum IGF-1) to predict lean mass decline among middle-aged
and older adults. Given the sample population demographic, results were analyzed examining the
total sample as well as for sex-specific differences.
Participant recruitment and participation
Participant recruitment primarily stemmed from electronic University advertisement
(Newswire) as well as flyer distribution and word of mouth. Four hundred twenty-seven
individuals were contacted regarding study participation. Of those contacted, 184 individuals
either did not respond to recruitment efforts or indicated no interest in participation. Based on the
pre-screening health history process, 170 individuals qualified for study participation and 60
were disqualified due to health history factors. Throughout the duration of the study, 13
individuals voluntarily withdrew due to personal reasons.
In total, 106 individuals of varying ages and activity levels participated in the study.
Variability in total sample size reported, per variable, were due to the following: no blood
sample successfully collected for serum analysis (n = 6), failure to successfully complete the
CHAMPS questionnaire (n = 30), and/or classifying as a statistical outlier via Boxplot analysis
(n = 20).
Participant demographics
Participant age ranged from 41-89 years, with the average age being 60 years (60.1 ±
11.1 y). Male (n = 38) and female participants (n = 68) were similar in age (male: 62.2 ± 10.6 y;
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female: 58.9 ± 11.3 y). Total sample and sex-specific data for anthropometric, body composition,
dietary protein intake, physical activity, and serological measures are reported in Table 6.
Independent samples t-test statistics detected significant sex differences among
anthropometric (height: t =10.35, p < .001 and weight: t = 5.72, p <.001) and lean tissue massrelated body composition measures (ASM: t = 15.85, p < .001; ASMIBMI: t = 14.24, p < .001);
and total LTM: t = 15.98, p < .001). On average, men were 16.3 cm (9%) taller than women and
weighed 16.9 kg (24%) more. Men generally had more lean mass, containing 49.8% more total
lean tissue mass (60.8 ± 7.1 kg) than women (40.6 ± 5.7 kg) and 13.7% less fat mass. When
examining only appendicular skeletal muscle mass, men also exhibited significantly more muscle
mass; 59.4% greater mass (27.1 ± 3.7 kg) than women (17.0 ± 2.8 kg). Relative to body mass,
appendicular skeletal muscle mass was significantly less (p < .001) among females (0.674 ±
0.121), as compared to males (1.022 ± 0.116).
Sex differences were also detected among the biomarkers (myostatin: t = 2.14, p < .05;
IGF-1: t = 3.12, p < .01) and dietary intake variables (caloric intake: t = 2.27, p < .05; total
protein intake: t = 2.83, p < .01) being analyzed. On average, biomarker concentration was
greater among men for both myostatin (18.4%) and IGF-1 (23.2%), as compared to females. In
relation to dietary intake variables, men consumed an average of 223.9 more calories per day
than women. Men also consumed 16.2 more grams of protein per day than women; however,
when calculated relative to body mass, men and women consumed equitable amounts of protein
(males: 0.95 ± 0.38 g/kg; females: 0.95 ± 0.36 g/kg). Sex-specific differences are indicated in
Table 6 and sex-specific age cohort descriptive statistics indicated in Tables 7 and 8.
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Table 6
Descriptive Statistics for All Participants
Total Sample (n = 106)
Female (n = 68)
Male (n = 38)
t
p-value
Variable
M ± SD
M ± SD
M ± SD
Age (y)
60.1 ± 11.1
58.9 ± 11.3
62.2 ± 10.6
1.47
.15
Height (cm)
170.2 ± 11.0
164.3 ± 7.8
180.6 ± 7.8
10.4
<.001
Weight (kg)
75.6 ± 16.7
69.5 ± 14.1
86.4 ± 15.4
5.72
<.001
BMI (kg/m2)
26.0 ± 5.1
25.8 ± 5.5
26.4 ± 4.1
0.63
.53
ASM (kg)
20.6 ± 5.8
17.0 ± 2.8
27.1 ± 3.7
15.9
<.001
ASMBMI
0.796 ± 0.205
0.674 ± 0.121
1.022 ± 0.116
14.2
<.001
Total LTM (kg)
47.9 ± 11.5
40.6 ± 5.7
60.8 ± 7.1
16.0
<.001
Total FM (kg)
24.3 ± 9.5
25.6 ± 9.8
22.1 ± 8.6
-1.80
.08
Myostatin (pg/mL)
2119.8 ± 821.6
1986.5 ± 667.2
2352.1 ± 1006.4
2.14
.04
IGF-1 (ng/mL)
52.5 ± 18.0
48.3 ± 16.7
59.5 ± 18.0
3.12
<.01
Caloric intake (kcal)
1645.5 ± 476.4
1569.4 ± 411.4
1793.3 ± 559.8
2.27
.03
Protein intake (g)
70.2 ± 28.7
64.5 ± 24.9
80.7 ± 32.5
2.83
<.01
Protein intake (g/kg)a 0.95 ± 0.37
0.95 ± 0.36
0.95 ± 0.38
0.05
.96
Energy expenditureb
4182.9 ± 2647.1
4282.6 ± 2600.1
3979.4 ± 2786.0
-0.46
.65
Note. M = mean; and SD = standard deviation. BMI = body mass index. ASM = appendicular skeletal muscle mass. LTM = lean
tissue mass. FM = fat mass. aProtein intake, measured in grams per kilogram body weight. bCaloric expenditure from weekly exerciserelated activity, measured in kilocalories. t = independent samples t-test value. Significance was set at α < 0.05.
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Table 7
Descriptive Statistics for Females, per Age Cohort
40-49 years
50-59 years
60-69 years
≥ 70 years
p-value
(n = 17)
(n = 18)
(n = 22)
(n = 11)
Height (cm)
164.6 ± 9.4
164.4 ± 7.9
164.7 ± 6.1
162.9 ± 9.0
.93
Weight (kg)
74.1 ± 18.3
66.6 ± 9.9
71.2 ± 13.9
63.8 ± 11.8
.20
BMI (kg/m2)
27.5 ± 7.2
24.8 ± 4.4
26.3 ± 5.5
24.0 ± 4.0
.32
ASM (kg)
18.9 ± 3.4
16.8 ± 1.6
16.6 ± 2.6
15.4 ± 2.2
.01
ASMBMI
0.71 ± 0.2
0.70 ± 0.1
0.64 ± 0.1
0.65 ± 0.1
.30
Total LTM (kg)
44.5 ± 7.0
40.2 ± 4.0
39.7 ± 5.3
37.3 ± 4.1
.01
Total FM (kg)
26.7 ± 12.6
23.9 ± 9.0
27.2 ± 8.5
23.2 ± 8.7
.58
Myostatin (pg/mL)
2037.0 ± 680.6
1983.9 ± 648.0
2002.7 ± 770.5
1900.1 ± 577.4
.97
IGF-1 (ng/mL)
60.7 ± 18.8
51.7 ± 15.2
40.6 ± 9.1
41.4 ± 18.1
.002
Caloric intake (kcal)
1565.2 ± 431.5
1495.2 ± 362.5
1665.5 ± 495.9
1497.8 ± 242.7
.56
Protein intake (g)
70.7 ± 25.5
59.6 ± 24.8
66.3 ± 24.8
59.9 ± 25.2
.55
Protein intake (g/kg)a
1.0 ± 0.4
0.9 ± 0.3
0.9 ± 0.3
1.0 ± 0.4
.81
Energy expenditureb
45834.0 ± 2931.9
3787.0 ± 2619.9
4990.2 ± 2233.0
3972.4 ± 2228.4
.68
Note. M = mean; and SD = standard deviation. BMI = body mass index. ASM = appendicular skeletal muscle mass. LTM = lean
tissue mass. FM = fat mass. aProtein intake, measured in grams per kilogram body weight. bCaloric expenditure from weekly exerciserelated activity, measured in kilocalories. t = independent samples t-test value. Significance was set at α < 0.05.
Variable
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Table 8
Descriptive Statistics for Males, per Age Cohort
40-49 years
50-59 years
60-69 years
≥ 70 years
p-value
(n = 6)
(n = 6)
(n = 16)
(n = 10)
Height (cm)
179.1 ± 9.1
179.8 ± 6.5
180.5 ± 5.9
182.3 ± 10.8
.87
Weight (kg)
80.8 ± 8.4
84.2 ± 10.4
86.3 ± 15.7
91.4 ± 20.4
.60
BMI (kg/m2)
25.3 ± 3.4
26.0 ± 2.5
26.6 ± 5.0
27.2 ± 4.1
.84
ASM (kg)
27.8 ± 3.0
28.1 ± 3.0
26.6 ± 2.9
27.0 ± 5.7
.81
ASMBMI
1.0 ± 0.1
1.1 ± 0.2
1.0 ± 0.1
1.0 ± 0.1
.44
Total LTM (kg)
60.9 ± 6.4
60.7 ± 5.7
60.3 ± 5.4
61.6 ± 10.7
.98
Total FM (kg)
21.8 ± 5.1
20.1 ± 8.5
20.7 ± 8.1
25.6 ± 11.0
.52
Myostatin (pg/mL)
2092.9 ± 769.8
2005.0 ± 350.1
2664.8 ± 1359.7
2149.0 ± 332.1
.42
IGF-1 (ng/mL)
62.1 ± 14.8
63.4 ± 6.6
53.3 ± 23.1
66.1 ± 12.2
.33
Caloric intake (kcal)
1992.3 ± 606.3
2012.3 ± 481.5
1841.9 ± 568.8
1461.3 ± 499.3
.56
Protein intake (g)
100.7 ± 26.4
81.0 ± 34.2
81.4 ± 29.8
67.7 ± 36.5
.55
Protein intake (g/kg)a
1.3 ± 0.3
1.0 ± 0.3
0.9 ± 0.3
0.8 ± 0.4
.81
Energy expenditureb
4222.5 ± 2144.2
3768.8 ± 2530.7
5294.1 ± 4004.0
2859.3 ± 2169.4
.68
Note. M = mean; and SD = standard deviation. BMI = body mass index. ASM = appendicular skeletal muscle mass. LTM = lean
tissue mass. FM = fat mass. aProtein intake, measured in grams per kilogram body weight. bCaloric expenditure from weekly exerciserelated activity, measured in kilocalories. t = independent samples t-test value. Significance was set at α < 0.05.
Variable
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Correlations
Pearson product moment correlation coefficients were used to assess the relationships
among the following variables: age, lean tissue mass, appendicular lean mass, appendicular lean
mass standardized for body mass index, serum myostatin, serum IGF-1, total protein intake,
protein intake relative to body mass, and exercise-related activity caloric expenditure (Table 4).
Sex-specific correlations for females and males are reported in Tables 10 and 11, respectively.
Age and lean mass measures. Pearson correlation results of the total sample (Table 9)
indicate age has an overall non-significant negative association with total lean tissue mass (r = .01, p = .94) and appendicular skeletal muscle mass (r = -.04, p = .69). This suggests that for
every year aged, total lean mass and appendicular skeletal muscle mass decline by .01 and .03 kg
among the total population, respectively. Similarly, sex-specific Pearson correlation results for
females, indicate age has a significant moderate negative association with both total lean tissue
mass (r = -.41, p = .001) and appendicular skeletal muscle mass (r = -.42, p = <.001). The
opposite is true for males. Among males, total lean tissue mass was a non-significant, positive
correlate with age (r = .01, p = .93) while appendicular skeletal muscle mass was a nonsignificant, weak negative correlate with age (r = -.14, p = .40). Overall, these results suggest
lean tissue mass declines with increasing age among individuals aged 40 years and older.
Age and serum biomarkers. Relationships between age and each biomarker (myostatin,
IGF-1) were examined via Pearson correlations for the total sample and each sex. Serum
myostatin presented as a non-significant correlate with age (r = .04, p = .69) and IGF-1 a nonsignificant, negative correlate with age (r = -.19, p = .06) among the total sample. However,
when examining sex-specific relationships, biomarker correlates presented differently for males
and females. Among the female sample, myostatin presented as a non-significant, negative
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correlate with age (r = -.02, p = .87), suggesting a very slight decrease in serum myostatin with
increasing age. The opposite was true for males; myostatin exhibited a non-significant, positive
correlation with age (r = .07, p = .71), suggesting a very slight increase in myostatin
concentration with increasing age. Examination of IGF-1 as a correlate with age indicated a
significantly, moderate, negative association among females (r = -.39, p = .002) and a nonsignificant association among males (r = .01, p = .94).
Altogether, variability exists among biomarker concentration in relation to age. From a
myostatin perspective, the total sample and male sample both display a non-significant, weak,
positive correlation, suggesting myostatin concentration to increase with age in both cohorts.
However, among females, a negligible, non-significant, negative association is present,
suggesting myostatin concentration to slightly decrease with advancing age. For IGF-1, the total
sample and female sample trends suggest IGF-1 concentrations decline with age, whereas the
non-significant, weak positive association among males suggests IGF-1 concentration slightly
increases with age.
Age and dietary protein intake. Dietary intake is known to alter with age due to many
biological factors. Pearson correlation data from the present investigation indicates a similar
trend for the total sample as well as both sexes. Total dietary protein, in relation to age, among
the total sample, females, and males indicated a weak, negative association; however, this
association was only significant among the male cohort (total sample: r = -.12, p = .22; female: r
= -.06, p = .66; male: r = -.33, p = .05). Dietary protein intake, relative to body mass, also
exhibited a negative association among the total sample and males; however, this association was
weak and non-significant among the total sample (r = -.14, p = .78) whereas it was significant
and moderate for the male sample (r = -.40, p = .02). The female cohort exhibited the only non-
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significant, positive association of relative dietary protein intake with age, although it was nonsignificant (r = .04, p = .78).
In summation, total dietary protein intake and dietary protein intake relative to body mass
present as negative correlates with age, although this association is only significant among the
male population. This suggest that total dietary protein intake may decline with age, and at a
more significant rate for males than female counterparts.
Age and exercise-related energy expenditure. Exercise-related energy expenditure
tends to decline with age due to a multitude of factors. This trend appears to hold true for the
total sample and males in the present investigation. Non-significant, negative associations were
present for exercise-related activity caloric expenditure among the total sample (r = -.01, p = .96)
and males (r = -.02, p = .93) in relation to age. This suggests energy expenditure from exerciserelated activity to minimally decline with increasing age among males and the total sample.
However, when examining only the female population, a non-significant, positive association
was present for exercise-related activity caloric expenditure in relation to age (r = .01, p = .96),
suggesting a very slight increase in exercise-related activity caloric expenditure among females
with progressing age. This association is congruous with the fact that females in this sample
tended to expend more calories related to exercise activities than males (Table 6).
Serum biomarkers and lean tissue mass measures. Serum myostatin and IGF-1
Pearson correlation analyses revealed both biomarkers to be significant correlates with total lean
tissue mass and appendicular skeletal muscle mass among the total sample population. For
myostatin, a weak, positive association was present in relation to both total lean tissue mass (r =
0.21, p = .04) and appendicular skeletal muscle mass (r = .21, p = .04). Similar positive, but
moderate, associations were present for IGF-1 in relation to total lean tissue mass (r = .36, p <
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.001) and appendicular skeletal muscle mass (r = .35, p < .001). Taken together, these data
suggest both biomarkers may slightly increase with progressing age for the total sample
population.
Sex-specific correlations were not entirely congruent with total sample findings in that
many associations were not significant at the sex-specific level and/or exhibited opposite
associations. Similar to the total sample findings, Pearson correlations for females indicate weak,
positive associations for myostatin in relation to total lean tissue mass (r = .20, p = .12) and
appendicular skeletal muscle mass (r = .16, p = .21); however, these associations are not
significant. In contrast to total sample findings, Pearson correlations for males indicate nonsignificant, negligible associations for myostatin in relation to total lean tissue mass (r = -.08, p =
.64) and appendicular skeletal muscle mass (r = -.04, p = .81). These findings suggest that when
examining serum myostatin based on sex, myostatin increases with age among females and
slightly decreases with age among males.
Regarding sex-specific IGF-1 associations with lean tissue mass measures, females
exhibited similar relationships to that of the total sample. Among females, IGF-1 exhibited a
positive, moderate association with both total lean tissue mass (r = .31, p = .02) and appendicular
skeletal muscle mass (r = .25, p = .05), but the association was only significant with relation to
total lean tissue mass. A similar positive trend was present among the male population; however,
the associations were both non-significant and weak (total lean tissue mass: r = .09, p = .58;
appendicular skeletal muscle mass: r = .10, p = .57). These associations suggest that among
males and females, IGF-1 concentration may increase with progressing age, but likelihood of
increase may be greater among females than males.
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Table 9
Descriptive Statistics and Correlations for Total Sample (n = 106)
Variable

Age

LTM

ASM

ASMBMI Myostatin IGF-1

PRO

DPI

LTM
-.01
(n = 106)
(.94)
ASM
-.04
.98**
(n = 106)
(.69)
(<.001)
ASMBMI
.02
.79**
.79**
(n = 105)
(.81)
(<.001) (<.001)
Myostatin
.04
.21*
.21*
.13
(n = 96)
(.69)
(.04)
(.04)
(.20)
IGF-1
-.19
.36**
.35**
.35**
-.02
(n = 98)
(.06)
(<.001) (<.001)
(.001)
(.89)
PRO
-.12
.32**
.33**
.21*
.03
.09
(n = 103)
(.22)
(.001)
(.001)
(.04)
(.76)
(.36)
DPI
-.14
-.06
-.06
.07
-.06
.004
.84**
(n = 103)
(.25)
(.54)
(.54)
(.51)
(.59)
(.97)
(<.001)
ERA Kcal
-.01
-.04
-.01
-.04
.05
.14
0.10
0.07
(n = 73)
(.91)
(.77)
(.94)
(.74)
(.70)
(.27)
(.41)
(.57)
Note. Entries on the main diagonal are Pearson’s r. Figures in parentheses are P values. LTM =
total lean tissue mass, measured in kilograms. ASM = appendicular skeletal muscle mass,
measured in kg. ASMBMI = appendicular skeletal muscle mass relative to body mass index. PRO
= total dietary protein intake, reported in grams. DPI = dietary protein intake, reported in grams
per kilogram body weight. ERA Kcal = exercise-related activity caloric expenditure, reported in
kilocalories. *correlation significant at the .05 level. **correlation significant at the .01 level.

Serum biomarkers and dietary protein intake. Dietary protein intake plays in
influential role in muscle mass maintenance and impacts physiological adaptations. As a result,
Pearson correlations were examined for serum myostatin and IGF-1 in relation to total dietary
protein intake and relative dietary protein intake (dietary protein intake per kilogram of body
mass). Total sample correlation analyses indicted myostatin to be a non-significant correlate of
total protein intake (r = .03, p = .76) and a non-significant correlative with relative dietary
protein intake (r = -.06, p = .59). This associative trend was similar when examining sex-specific
influences. For females, myostatin was a non-significant, weak, positive correlate with total
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protein intake (r = .12, p = .36) and a negligible correlate with relative dietary protein intake (r =
.03, p = .83). Among males, myostatin exhibited a non-significant, weak association with
myostatin, but in the negative direction for both total protein intake (r = -.19, p = .28) and
relative dietary protein intake (r = -.17, p = .36). Conclusively, myostatin displays no significant
association with total dietary protein intake when examining relationships for the entire sample
and sex-specific samples. This is to be expected given exercise presents as a more influential
factor on myostatin regulation than dietary protein intake.
In relation to IGF-1, Pearson correlation results indicated non-significant, weak,
associations for both total dietary protein intake and dietary protein intake relative to body mass.
Among the total sample, IGF-1 associations were negligible for both total protein intake (r = .09,
p = .36) and relative dietary protein intake (r = .004, p = .97). A similar association was
prevalent among the female sample. IGF-1 exhibited a non-significant, negligible correlation for
both total protein intake (r = .08, p = .53) and relative dietary protein intake (r = .07, p = .62).
However, this association was not present among the male population. In relation to both total
protein intake and relative dietary protein intake, IGF-1 presented as a non-significant, weak,
negative correlate (total protein intake: r = -.14, p = .43; relative dietary protein intake: r = -.14,
p = .44). Although not conclusive, these results suggest that IGF-1 concentration may slightly
increase with dietary protein intake, but only among the total sample and females; among males,
increased dietary protein intake may result in decreased serum IGF-1 concentration.
Serum biomarkers and exercise-related energy expenditure. Physical activity and
exercise play roles in maintenance of muscle mass with age. As such, associations were
examined for serum biomarkers in relation to exercise-related caloric expenditure. Pearson
correlations indicate serum myostatin to have a non-significant, weak, positive association with
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exercise-related caloric expenditure among the total sample (r = .05, p = .70) and females (r =
.16, p = .30). However, among males, there was a non-significant, weak, negative association
between serum myostatin and exercise-related energy expenditure (r = -.27, p = .23).
Consequently, the relationship between serum myostatin concentration and exercise-related
activity remains inconclusive.
In contrast to serum myostatin associations, IGF-1 concentration had a consistent
association with exercise-related caloric expenditure across the total sample and sex-specific
investigations. Pearson correlations indicated IGF-1 to have a weak, positive association with
exercise-related activity energy expenditure for the total sample (r = .14, p = .27), females (r =
.19, p = .21), and males (r = .12, p = .59). Although not significant, these associations suggest
IGF-1 concentration increases as exercise-related activity caloric expenditure increases for the
entire sample population, regardless of sex.
Multiple regression
Multiple regression analysis was used to develop two models for predicting appendicular
skeletal muscle mass decline among men and women aged 40 years and older. In model 1,
regression analysis was used to predict the dependent variable (appendicular skeletal muscle
mass) from a set of predictor variables (age, sex, myostatin, IGF-1) primarily related to
biomarker influence on muscle mass. In model 2, regression analysis was also used to predict
appendicular skeletal muscle mass (DV), but the set of predictor variables included factors
influential on biomarker prevalence (age, sex, myostatin, IGF-1, protein intake, exercise).
Model 1. Multiple regression analysis was used to develop a model for predicting
appendicular skeletal muscle among men and women aged 40 years and older based on
biomarkers. Regression coefficients for the total sample population are shown in Table 12. The
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four predictor model accounted for 78% of the variance in ASM (F(4,89) = 78.92, p < .001).
Among the total sample, sex was the only predictor variable significantly contributing to the
effects of the full model (p < .001), accounting for 73.5% of the variance. Age, serum myostatin,
and serum IGF-1 did not significantly contribute to the model, but accounted for 6.6%, <1.0%,
and 1.4% of the variance in ASM, respectively.

Table 10
Descriptive Statistics and Correlations for Females (n = 68)
Variable

Age

LTM

ASM

ASMBMI Myostatin IGF-1

PRO

DPI

Total LTM
-.41**
(n = 68)
(.001)
ASM
-.42**
.95**
(n = 68)
(<.001) (<.001)
ASMBMI
-.20
.39**
.36**
(n = 68)
(.11)
(.001)
(.002)
Myostatin
-.02
.20
.16
-.11
(n = 61)
(.87)
(.12)
(.21)
(.39)
IGF-1
-.39**
.31*
.25
.22
-.13
(n = 61)
(.002)
(.02)
(.05)
(.08)
(.32)
PRO
-.06
.29*
.27*
.06
.12
.08
(n = 67)
(.66)
(.02)
(.03)
(.62)
(.36)
(.53)
DPI
.04
-.03
-.07
.22
.03
.07
.86**
(n = 67)
(.78)
(.81)
(.58)
(.08)
(.83)
(.62)
(<.001)
ERA Kcal
.01
.01
.09
-.14
.16
.19
-.15
-.14
(n = 49)
(.96)
(.93)
(.54)
(.33)
(.30)
(.21)
(.33)
(.35)
Note. Entries on the main diagonal are Pearson’s r. Figures in parentheses are P values. LTM =
total lean tissue mass. ASM = appendicular skeletal muscle mass. ASMBMI = appendicular
skeletal muscle mass relative to body mass index. PRO = total dietary protein intake, reported in
grams. DPI = dietary protein intake, reported in grams per kilogram body weight. ERA Kcal =
exercise-related activity caloric expenditure, reported in kilocalories. *correlation significant at
the .05 level. **correlation significant at the .01 level.
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Table 11
Descriptive Statistics and Correlations for Males (n = 38)
Variable

Age

LTM

ASM

ASMBMI Myostatin IGF-1

PRO

DPI

LTM
.01
(n = 38)
(.93)
ASM
-.14
.91*
(n = 38)
(.40)
(<.001)
ASMBMI
-.19
.27
.34*
(n = 37)
(.25)
(.11)
(.04)
Myostatin
.07
-.08
-.04
-.04
(n = 35)
(.71)
(.64)
(.81)
(.81)
IGF-1
.01
.09
.10
.15
-.04
(n = 37)
(.94)
(.58)
(.57)
(.39)
(.81)
PRO
-.33*
.05
.10
-.11
-.19
-.14
(n = 36)
(.05)
(.76)
(.56)
(.52)
(.28)
(.43)
DPI
-.40*
-.26
-.19
-.05
-.17
-.14
.90**
(n = 36)
(.02)
(.13)
(.26)
(.76)
(.36)
(.44) (<.001)
ERA Kcal
-.02
.03
.03
.25
-.27
.12
.47*
.44*
(n = 24)
(.93)
(.91)
(.88)
(.24)
(.23)
(.59)
(.02)
(.03)
Note. Entries on the main diagonal are Pearson’s r. Figures in parentheses are P values. LTM =
total lean tissue mass. ASM = appendicular skeletal muscle mass. ASMBMI = appendicular
skeletal muscle mass relative to body mass index. PRO = total dietary protein intake, reported in
grams. DPI = dietary protein intake, reported in grams per kilogram body weight. ERA Kcal =
exercise-related activity caloric expenditure, reported in kilocalories. *correlation significant at
the .05 level. **correlation significant at the .01 level.

Given the significant contribution of sex as a predictor variable for this model, sexspecific models were also examined. Regression coefficients for females and males are shown in
Table 13 and Table 14, respectively. The three-predictor model accounted for a total of 14.7%
and 9.3% of the variance in ASM among females (F(3,55) = 3.17, p = .031) and males (F(3,31)
= 1.06, p = .38), respectively. Among the female sample, neither of the predictor variables
significantly contributed to the model, but did account for 4.7% (age), 3.8% (myostatin), and
3.7% (IGF-1) of model variability, respectively. Similarly, among males, neither of the predictor
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variables significantly contributed the model; age accounted for the largest percentage of model
variability (age: 8.4%; myostatin and IGF-1: < 1.0%).
Although many of the predictors were insignificant model contributors, model 1 indicates
age is a more influential predictor of appendicular skeletal muscle mass than serum biomarkers,
regardless of model examination for the total sample or sex. Biomarkers accounted for the
greatest amount of variability among the female sample (myostatin: 3.8%; IGF-1: 3.7%) and the
least amount of variability among males (myostatin and IGF-1: <1.0%) and the total sample
(myostatin: <1.0%; IGF-1: 1.4%). Taking everything into account, biomarkers present as best
use among females only, despite their lack of significance in model contribution.
Model 2. Multiple regression analysis was also used to develop a model for predicting
appendicular skeletal muscle mass among men and women aged 40 years and older based on
serum levels of myostatin and IGF-1 as well as influential regulators of each biomarker; exercise
and dietary protein intake, respectively. Regression coefficients for the total sample population
are shown in Table 15. The six-predictor model for the total sample population accounted for
81.3% of the variance in ASM (F(6,57) = 41.32, p < .001). Among the total sample, sex (p <
.001) and total protein intake (p < .05) were the only predictor variables significantly
contributing to the effects of the full model, accounting for 70.2% and 10.7% of the variance,
respectively. Age, serum myostatin, serum IGF-1, and total exercise-related activity caloric
expenditure did not significantly contribute to the model, but accounted for 4.9% (age), <1.0%
(myostatin), 1.4% (IGF-1), and <1.0% (exercise-related activity caloric expenditure) of the
variance in ASM.
Regression coefficients for females and males are shown in Table 16 and Table 17,
respectively. The five-predictor model accounted for 13.4% and 40.4% of the variance in ASM
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among females (F(5,36) = 1.12, p = .37) and males (F(5,16) = 2.17, p = .11), respectively.
Among the female sample, neither of the predictor variables significantly contributed to the
model but accounted for <1.0% (age and myostatin), 1.8% (IGF-1), 6.3% (total protein intake),
and 1.5% (exercise-related activity caloric expenditure) of model variability. Among males, only
total protein intake significantly contributed to the model, accounting for 21.2% of the variance
(p = .05). All other variables, although not significant, did contribute to model variability: age
(14.5%), myostatin (<1.0%), IGF-1 (12.5%), and exercise-related activity energy expenditure
(1.8%).
Altogether, sex was again the most significant model predictor, resulting in sex-specific
analysis. Of the sex-specific five predictor model (age, myostatin, IGF-1, total dietary protein
intake, exercise-related activity caloric expenditure), total dietary protein intake was the most
influential model contributor accounting for 21.2% of the variability for males and 6.3% for
females.

Table 12
Multiple Linear Regression for Age, Sex, and Biomarker Variables on Appendicular Skeletal
Muscle Mass for the Total Sample Population (n = 94)
Predictors
B
SE B
Age
-0.07
0.03
Sex
-10.2
0.65
Myostatin
0.00
0.001
IGF-1
0.02
0.02
Note. Significance was set at α < 0.05.

β
-0.13
-0.86
0.03
0.06

t
-2.52
-15.7
0.63
1.13

p
0.01
<.001
0.53
0.26
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Table 13
Multiple Linear Regression for Age and Biomarker Variables on Appendicular Skeletal Muscle
Mass for Female Sample Population (n = 59)
Predictors
B
SE B
Age
-0.05
0.03
Myostatin
0.001
0.001
IGF-1
0.03
0.02
Note. Significance was set at α < 0.05.

β

t
-0.22
0.19
0.20

p
-1.64
1.47
1.50

0.11
0.15
0.15

Table 14
Multiple Linear Regression for Age and Biomarker Variables on Appendicular Skeletal Muscle
Mass for Male Sample Population (n = 35)
Variable
B
SE B
Age
-0.10
0.06
Myostatin
0.00
0.001
IGF-1
0.02
0.03
Note. Significance was set at α < 0.05.

β

t
-0.28
-0.02
0.08

p
-1.67
-0.11
0.49

0.10
0.91
0.63

Table 15
Multiple Linear Regression for Age, Sex, Biomarker, Nutrition and Exercise Variables on
Appendicular Skeletal Muscle Mass for the Total Sample Population (n = 64)
Variable
B
SE B
β
t
p
Age
-0.05
0.03
-0.11
-1.72
0.09
Sex
-9.26
0.80
-0.81
-11.6
<.001
Myostatin
<.001
0.001
0.01
0.20
0.84
IGF-1
0.02
0.02
0.06
0.92
0.36
Total PRO
0.03
0.01
0.16
2.61
0.01
ERA Kcal
6.1x10-5
<.001
0.03
0.49
0.63
Note. Total PRO = total dietary protein intake. ERA Kcal = exercise-related activity caloric
expenditure. Significance was set at α < 0.05.
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Table 16
Multiple Linear Regression for Age, Biomarker, Nutrition and Exercise Variables on
Appendicular Skeletal Muscle Mass for the Female Sample Population (n = 42)
Variable
B
SE B
β
t
p
Age
-0.02
0.04
-0.08
-0.49
0.63
Myostatin
<.001
0.001
0.04
0.24
0.81
IGF-1
0.02
0.02
0.15
0.82
0.42
Total PRO
0.02
0.01
0.25
1.56
0.13
ERA Kcal
<.001
<.001
0.12
0.74
0.47
Note. Total PRO = total dietary protein intake. ERA Kcal = exercise-related activity caloric
expenditure. Significance was set at α < 0.05.

Table 17
Multiple Linear Regression for Age, Biomarker, Nutrition and Exercise Variables on
Appendicular Skeletal Muscle Mass for the Male Sample Population (n = 22)
Variable
B
SE B
β
t
p
Age
-0.10
0.06
-0.34
-1.65
0.12
Myostatin
0.001
0.002
0.07
0.34
0.74
IGF-1
0.09
0.06
0.31
1.51
0.15
Total PRO
0.06
0.03
0.49
2.08
0.05
ERA Kcal
<.001
<.001
-0.13
-0.54
0.60
Note. Total PRO = total dietary protein intake. ERA Kcal = exercise-related activity caloric
expenditure. Significance was set at α < 0.05.

Secondary analysis
Following the conduction of all primary analyses, a secondary analysis was conducted
via one-way ANOVA to identify differences across decades (40-49 years, 50-59 years, 60-69
years, 70+ years) for the following variables: total lean tissue mass, appendicular skeletal muscle
mass, appendicular skeletal muscle mass standardized for body mass index, serum myostatin,
serum IGF-1, total protein intake, protein intake relative to body mass, and exercise-related
activity energy expenditure. The significance value for this analysis was set at α < .05 and all
variables of significance further examined via Bonferroni post-hoc.
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In short, total sample results indicated only IGF-1 to be significantly different across
decades (F(3,102) = 0.35, p = .03). Statistically significant decade differences for females were
present for IGF-1 (F(3,57) = 5.65, p = .002), total lean tissue mass (F(3,64) = 4.60, p = .006),
and appendicular skeletal muscle mass (F(3,64) = 4.71, p = .005); however, there were no
statistically significant differences among males for any variables across age cohorts. Detailed
results are displayed in Figures 1-7.
Decade differences for lean tissue mass measures. Examination for all data related to
lean tissue mass measures (total lean tissue mass and appendicular skeletal muscle mass) yielded
varying results across age decades; however, decade differences were only significant among
females (Figures 1 and 2). Interestingly, among the total sample, total body lean mass differences
were marginal across age cohorts: 40-49-year-old: 48.76 ± 9.97 kg; 50-59-year-old: 45.31 ±
10.07 kg); 60-69-year-old: 48.42 ± 11.58 kg; 70+ year old: 48.92 ± 14.66 kg. The greatest
difference in total body mass was seen between the 40-49 year and 50-59-year groups; average
total lean mass among the 50-59-year-old group was 7.1% less than the 40-49-year-old group.
Total lean tissue mass was also greater among the 60-69-year-old group, as compared to the 5059-year-old age group. On average, 60-69-year-olds had 6.9% greater total lean tissue mass than
their younger 50-59-year-old counterparts. Finally, the 70+ year old individuals exhibited 1.0%
greater total lean tissue mass than individuals aged 60-69 years old (Figure 1). A similar trend
was examined for appendicular skeletal muscle mass: individuals aged 50-59 years of age had
7.6% less appendicular skeletal muscle mass compared to individuals in the 40-49 year old
group; individuals in the 60-69 year old group had 6.0% greater appendicular skeletal muscle
mass than their younger 50-59 year old counterparts; and individuals in the 70+ year old group
had 0.7% greater appendicular skeletal muscle mass than the 60-69 year old group (Figure 2).
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Lean tissue mass examination across decades for females indicated significant differences
for both total lean tissue mass (p = .006) and appendicular skeletal muscle mass (p = .005).
Significant differences for total lean tissue mass and appendicular skeletal muscle mass were
present between the 40-49-year-old and 60-69-year-old age groups, as well as between the 4049-year-old and 70+ year old age groups. On average, 60-69-year-old females and females aged
70+ years had significantly less total lean tissue mass than individuals aged 40-49 years (60-69
years: 10.6% less, p = .05; 70+ years: 16% less, p = .006; Figure 1). Similarly, females 60-69
years and 70+ years of age had significantly less appendicular skeletal muscle mass than
individuals aged 40-49 years (60-69 years: 12.3% less, p = .04; 70+ years: 18.3% less, p = .005;
Figure 2). Outside of significant differences, total lean tissue mass and appendicular lean tissue
mass among females were progressively lower across age cohorts. On average, 50-59 year old
females exhibited 9.7% less total lean tissue mass than the 40-49 year old age group; 60-69 year
old females exhibited 1.1% lower total lean tissue mass than the 50-59 year old age group; and
females aged 70+ years exhibited 6.0% less total lean tissue mass than females aged 60-69 years.
The same trend held true for decline in appendicular skeletal muscle mass. Females in the 50-59
year old group had 11.2% less appendicular muscle mass than 40-49 year old group; 60-69 year
old females had 1.2% less appendicular skeletal muscle mass than the 50-59 year old females;
and females aged 70+ years of age had 6.9% less appendicular skeletal muscle mass than the 6069 year old females.
Contrary to the trends for total lean tissue mass and appendicular skeletal muscle mass
among the total sample and females, declines in muscle mass among males was not significant
nor as large. Total lean tissue mass was slightly lower (0.4%) among the 50-59-year-old age
group, as compared to the 40-49-year-old group. Similarly, total lean tissue mass was slightly
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lower (0.6%) among the 60-69-year-old age group, as compared to the 50-59-year old group.
Interestingly, the 70+ year old age group had 2.2% more total lean tissue mass than that of the
60-69-year-old group. When examining these tendencies with appendicular skeletal muscle
mass, males aged 50-59 years exhibited 1.1% greater appendicular lean skeletal muscle mass
than the 40-49-year-old group whereas the 60-69-year-old group of males exhibited 5.5% less
appendicular skeletal muscle mass than the 50-59-year-old group. Similar to the total lean tissue
mass measure, appendicular skeletal muscle mass among males 70+ years of age was 1.5%
greater than that of the 60-69-year-old group.
Taken together, these findings suggest lean tissue mass measures to be variable
depending upon the sex and age groups being examined. Viewed from a total sample
perspective, the most drastic, though insignificant, decrease in lean mass measures appeared to
take place between the 40-49-year-old age group and 50-59-year-old age group. This trend held
true for females, but not for males; males generally exhibited less of a decline between decades
than females. The most significant variability existed among the female population in which
decade differences were prominent. In general, females had lower total and appendicular skeletal
muscle mass, as compared to men. The ages in which the declines were most significant for
women were amongst those aged 60-69 years and 70+ years. Overall, these results suggest lean
tissue mass decline is present with age, but the extent to the decline is sex specific.
Decade differences for serum biomarker measures. All data for total sample and sexspecific decade differences in serum myostatin and IGF-1 are displayed in Figures 3 and 4. From
a total sample perspective, serum myostatin measures were variable across all age cohorts;
highest serum myostatin concentrations were present among the 60-69-year-old age group
(2314.28 ± 1121.91 pg/mL) and lowest among the 50-59-year-old age group (1989.18 ± 580.58
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pg/mL). Although serum myostatin concentrations were not significantly different between age
groups (Figure 3), the 50-59-year-old group exhibited a 3% lower myostatin concentration, as
compared to the 40-49-year-old group. The greatest differences in myostatin concentration were
between the 50-59 and 60-69-year-old cohort and the 60-69 and 70+ year old age cohort.
Myostatin concentration was 16.3% greater among the 60-69-year-old group, as compared to the
50-59-year-old group and 13.4% lower among the 70 and older age group, as compared to the
60-69-year-old cohort.

Figure 1. Total Lean Tissue Mass across Decades. The distribution of total lean tissue mass
across decades for the total sample, males, and females. *p < .05. Δ p < .01
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Serum IGF-1 concentrations among the total population were also variable and
significantly differed between the 40-49-year-old and 60-69-year-old age group (p = .02; Figure
4). IGF-1 concentrations were greatest among the 40-49-year-old age group (61.14 ± 17.24
ng/mL) and lowest among the 60-69-year-old age group (46.42 ± 17.93 ng/mL), creating a
24.1% difference between the two age cohorts. Large, but less drastic and non-significant,
variability was also seen in comparing the other age cohorts. In short, IGF-1 concentration was
10.7% lower in the 50-59 year old age group, as compared to the 40-49 year old group; IGF-1
concentration was 15% lower in the 60-69-year-old age group, as compared to the 50-59 year old
group; and IGF-1 concentration was 13.1% greater in the 70 and older age group, as compared to
the 60-69-year-old age group. Taken together, the total sample exhibits decrements in IGF-1
concentration until the age of 70+ years, in which an increase again occurs.
The trend for biomarker concentration variability held true in sex-specific evaluations.
Like the total sample, significant differences in myostatin concentration were not present among
the female or male samples (Figure 3). In contrast to the total sample results, serum myostatin
concentration among females was greatest among the 40-49-year-old age group (2036.97 ±
680.62 pg/mL) and lowest among the 70+ year old age group (1986.53 ± 577.42 pg/mL).
Declines in serum myostatin concentration were greatest between the 40-49-year-old and 50-59year-old cohort (2.6% decline) and from the 60-69-year-old to 70+ year old cohort (5.1%
decline). On average, myostatin concentration was only slightly higher between the 50-59-yearold to 60-69-year-old cohort; individuals in the 60-69-year-old group had a 0.9% greater
myostatin concentration than the 50-59-year-old group.
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Figure 2. Appendicular Skeletal Muscle Mass across Decades. The distribution of appendicular
skeletal muscle mass (ASM) across decades for the total sample, male, and females.
Relative to the total sample and females, myostatin concentration among males was most
like that of the total sample. Greatest myostatin levels were present in the 60-69-year-old group
(2664.77 ± 1359.69 pg/mL) and lowest among the 50-59-year-old age group (2004.96 ± 350.12
pg/mL) among males. The greatest increase in myostatin concentration was exhibited from the
50-59-year-old to 60-69-year-old age group, increasing by 32.9%. Myostatin concentrations
were 4.2% lower in the 50-59-year-old age group, as compared to the 40-49-year-old age group,
and 19.4% lower in the 70+ year old age group, compared to the 60-69 year old group.
Altogether, myostatin exhibited no clear trend for increasing or decreasing across age cohorts but
exhibited a pattern of fluctuation over decades (concentration decline between 40-49 years and
50-59 years; concentration increase between 50-59 years to 60-69 years; concentration decline
from 60-69 years to 70+ years).
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Figure 3. Serum Myostatin Concentrations across Decades. The distribution of serum myostatin
across decades for the total sample, males, and females.
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Figure 4. Serum IGF-1 Concentrations across Decades. The distribution of serum IGF-1
concentrations across decades for the total sample, males, and females. *p < .05. Δ p < .01
In comparison to total sample results, significant differences between age cohorts were
also prevalent for IGF-1 concentration among females (p = .002; Figure 4). The significant
differences were present between the 40-49-year-old group and the 60-69-year-old group (p =
.003; 33.1% decline) as well as between the 40-49-year-old group and the 70+ year old group (p
= .02; 37.1% decline). IGF-1 was most concentrated among the 40-49-year-old group (60.68 ±
18.82 ng/mL) and least concentrated in the 60-69-year-old age group (40.60 ± 9.12 ng/mL).
Although not significant, IGF-1 concentration was 14.8% lower in the 50-59-year-old group
(51.68 ± 15.17 ng/mL), compared to the 40-49-year-old age group and 21.4% lower in the 6069-year-old age group, as compared to the 50-59-year-old age group (51.68 ± 15.17 ng/mL).
Interestingly, IGF-1 concentrations were 2% greater in the 70+ year old age group (41.43 ±
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18.06 ng/mL), as compared to the 60-69-year-old age group. Overall, among females, significant
IGF-1 concentration declines were prominent among both the 60-69-year-old and 70+ year old
age cohorts, as compared to the 40-49-year-old age cohort. Declines in IGF-1 were still
prominent between the 50-59-year-old and 60-69-year-old age cohorts, but these declines were
not sustained in the 70 years and older age group. Altogether, these results suggest IGF-1
concentrations to decline among females until age 70 and older, when IGF-1 concentrations may
again increase.
In contrast to both total sample and female results for IGF-1, the male cohort did not
exhibit significant differences in IGF-1 concentration across decades (Figure 4). Consistent with
total sample and female results, lowest IGF-1 concentration was present among the 60-69-yearold age group (53.33 ± 23.12 ng/mL); however, the greatest concentration of IGF-1 was present
among the 70 and older age group (66.06 ± 12.19 ng/mL). From decade to decade, IGF-1
concentrations were 2% greater in the 50-59-year-old group than the 40-49-year-old group and
23.9% greater in the 70+ group than the 60-69-year-old group. Conversely, IGF-1 concentrations
were 15.8% lower in the 60-69-year-old group, as compared to the 50-59-year-old group.
Although these results were not significant, the findings were similar to that of myostatin in that
there was no clear trend for IGF-1 concentration fluctuation across age cohorts among males;
however, there were a series of concentration increases and decreases across age cohorts among
males (concentration increase between 40-49-year-old to 50-59-year-old groups; concentration
decrease between 50-59-year-old to 60-69-year-old groups; concentration increase between 6069-year-old and 70+ year old groups).
Decade differences for dietary protein intake. Analysis of total dietary protein intake
and dietary protein intake relative to body mass indicated no significant sex-specific or total
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sample differences across age cohorts (Figure 5 and 6). Overall, the 40-49-year-old age group
consumed the greatest amount of total protein for the total sample (78.91 ± 28.58 grams),
females (70.74 ± 25.49 grams) and males (100.67 ± 26.44 grams). Relative to body mass, total
dietary protein intake yielded similar results (Figure 6). The greatest amount of total dietary
protein intake, relative to body mass, was also consumed the 40-49-year-old age group for the
total sample (1.08 g/kg), females (1.02 g/kg), and males (1.26 g/kg). Conversely, the least
amount of total dietary protein intake was consumed among individuals aged 70 years and older
for the total sample (63.65 ± 30.56 grams) and males (67.74 ± 36.52 grams), whereas females in
the 50-59 year old age group consumed the least amount of total dietary protein (59.62 ± 24.78
grams).
Looking specifically at the total sample, total dietary protein intake was greatest among
individuals aged 40-49 years. On average, individuals aged 50-59 years consumed 17.7% less
total dietary protein than those aged 40-49 years. Individuals aged 60-69 years consumed 11.0%
more total dietary protein than those in the 50-59-year-old group and 11.8% more than those
aged 70 years or older. Relative to body mass, similar trends were observed. Relative dietary
protein intake was 15.7% less in the 50-59-year-old group (0.91 g/kg), compared to the 40-49year-old group. Conversely, the 60-69-year-old age group consumed 2.9% more relative dietary
protein (0.94 g/kg), as compared to the 50-59-year-old group. Relative dietary protein intake was
again lower in the oldest age cohort; individuals aged 70+ years consumed 5.7% less (0.88 g/kg)
than the 60-69-year-old group.
Total dietary protein intake among females was like that of the total sample in that
individuals aged 40-49 years consumed the greatest amount of total dietary protein. Additionally,
the trend for total dietary protein intake was similar to that of the total sample: females 50-59
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years consumed 15.7% less protein than females aged 40-49 years; females 60-69 years of age
consumed 11.2% more total dietary protein than females aged 50-59 years; and females aged 70
and older consumed 9.6% less total dietary protein than females aged 60-69 years. Different
from the total sample, females in the 50-59-year-old age group consumed the least amount of
protein (59.62 ± 24.78 grams), as compared to their younger and older counterparts (40-49 years:
70.74 ± 25.49 grams; 60-69 years: 66.29 ± 24.85 grams; 70+ years: 59.93 ± 25.21 grams);
however, these differences were not statistically significant. Relative to total body mass, dietary
protein intake was 11.5% less among the 50-59-year-old group (0.90 g/kg) as compared to the
40-49-year-old group (1.02 g/kg). Individuals in the 50-59-year-old and 70+ year-old age groups
consumed 3.8% and 4.6% more relative total dietary protein than those in the 60-69-year-old
group, respectively.
Male cohort findings were like that of the total sample and females in that males in the
40-49-year-old age group (100.67 ± 26.44 grams) consumed the greatest amount of total protein.
Similarly, males in the 70+ years age group consumed the least amount of total dietary protein
(67.74 ± 36.52 grams). The trend for total dietary protein intake among men was resembled that
of the total sample and females: males aged 50-59 years consumed 19.5% less total dietary
protein than the 40-49 year old group; males 60-69 years of age consumed 0.4% more total
dietary protein intake than their younger, 50-59 year old males; and males aged 70+ years
consumed 16.7% less total dietary protein than their 60-69 year old counterparts. In contrast,
relative dietary protein intake trends were different among males. Males aged 50-59 years and
60-69 years had the same dietary protein intake, relative to body mass (50-59 years: 0.95 ± 0.33
g/kg; 60-69 years: 0.95 ± 0.32 g/kg). The greatest differences in relative dietary protein intake
were among the 40-49-year-old group to 50-59-year group and the 60-69-year-old to 70+ year
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old groups. On average, the 50-59-year-old group consumed 24.3% less relative dietary protein
compared to the 40-49-year-old group and the 70+ year old group consumed 17.2% less than the
60-69-year-old group. Again, none of these differences were significant. Overall, the trend for
dietary protein intake across the sample population indicates protein intake may decline from 4049 years of age, increase from 50-59 years to 60-69 years of age, and again decline from 60-69
years of age to 70+ years of age.
Decade differences for exercise-related activity energy expenditure. Evaluation of
exercise-related activity energy expenditure among the total sample indicated no significant
differences were present across decades (Figure 7). Decline in exercise-related activity energy
expenditure was prominent from the 40-49-year-old to 50-59-year-old age groups (16.0%
decline) and again from the 60-69-year-old to 70+ year-old age groups (34.1% decline). The
greatest increase in exercise-related activity energy expenditure was present between the 50-59year-old (3782.43 ± 2542.73 kcal) and 60-69-year-old (5120.46 ± 2979.14 kcal) decades. On
average, individuals in the 60-69-year-old group expended 35.4% and 34.1% more calories from
exercise-related activity than 50-59-year-old and 70+ year-old groups, respectively. Overall,
exercise-related activity energy expenditure was greatest among the 60-69-year-old age group
and least among the 70 and older age group (3373.05 ± 2108.75 kcal), suggesting the seventh
decade of life to be the most active in this sample.
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Figure 5. Total Dietary Protein Intake across Decades. The distribution of total protein intake
across decades for the total sample, males, and females are displayed.
Similarly, no significant differences in exercise-related activity caloric expenditure were
present across decades for females (Figure 7). The 60-69 year old age group appeared to be most
active among females, expending 31.8% more calories from exercise-related activity than that of
the 50-59 year old group (3786.96 ± 2619.87 kcal) and 20.4% more than the 70+ year old group
(3972.42 ± 2228.36 kcal). Different from that of the total sample, females in the 50-59-year-old
age group expended the fewest number of calories from exercise-related activity. On average,
50-59-year-old females expended 17.4% and 4.9% fewer calories from exercise-related activity
than females aged 40-49 years (4583.96 ± 2931.86 kcal) and 70+ years, respectively. Overall,
exercise-related activity energy expenditure was greatest among the 60-69-year-old age group
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and least among the 50-59-year-old age group, suggesting the seventh decade of life to be the
most active among females in the present investigation.
Exercise-related activity energy expenditure for males was like that of the total sample
and females in that no significant differences in caloric expenditure were present across decades
(Figure 7). Likewise, males in the sixth decade of life expended 10.7% fewer calories from
exercise-related activity than their counterparts in the fifth decade of life. On average, males
aged 60-69 years expended the greatest amount of exercise-related energy (5294.14 ± 4003.97
kcal) and males aged 70+ years expended the least amount (2859.31 ± 2169.37 kcal).
Additionally, the 60-69-year-old males expended 40.5% more exercise-related activity energy
than the 50-59-year-old group (3768.84 ± 2530.68 kcal) and 46% more exercise-related activity
energy than the 70 and older age group. Taken together, examination of exercise-related activity
caloric expenditure among the present sample suggests physical activity to decline from age 4049 years to 50-59 years of life, be greatest during 60-69 years of age, and again decline from age
70 years onward.
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Figure 6. Total Dietary Protein Intake across Decades, Relative to Body Mass. The distribution
of relative protein intake across decades for the total sample, males, and females are displayed.
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Figure 7. Exercise-related Activity (ERA) Energy Expenditure across Decades. The distribution
of exercise related activity (ERA) energy expenditure across decades for the total sample, males,
and females are displayed.
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CHAPTER FIVE
DISCUSSION

Understanding the multifactorial nature and pathophysiological complexity of sarcopenia,
the purpose of the present investigation was to provide evidence supporting the use of serum
biomarkers for prediction of appendicular skeletal muscle mass among middle-aged and older
adults. Myostatin and IGF-1 were of specific interest given their respective catabolic and
anabolic properties as well as mechanistic links to skeletal muscle mass accretion. Overall, it was
found that neither biomarker significantly contributed to the appendicular skeletal muscle mass
prediction model.
Regression analyses
Model 1: Serum myostatin and IGF-1. Prediction models utilizing blood biomarkers
are starting to become more prominent in the literature for areas related to chronic conditions
prominent with aging; however, these models are limited and have focused on anywhere from
one to 21 different biomarkers, making it difficult to delineate which biomarkers are most
influential in the prediction models (Calvani et al., 2018; Chang et al., 2017; Kwak et al., 2018;
Payette et al., 2003). The present investigation narrowed the scope of biomarker investigation by
only examining myostatin and IGF-1 as they related specifically to appendicular skeletal muscle
mass; however, only one other study has examined these specific biomarkers (Kwak et al.,
2018).
Contrary to the proposed hypothesis, serum myostatin and IGF-1 were not significant
predictors of appendicular skeletal muscle mass; however, of the two, IGF-1 presented as the
more promising biomarker, even though only accounting for 1.4% of model variability for the
preset sample. Regarding myostatin, these results are similar to that of the study conducted by
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Kwak and colleagues, where myostatin and IGF-1 were utilized in battery of 21 biomarkers for
prediction of sarcopenia (Kwak et al., 2018). Similar to results of the present investigation, Kwak
and colleagues (Kwak et al., 2018) identified serum myostatin was not a significant contributor
to the prediction of sarcopenia. In contrast to the current investigation, IGF-1 presented as a
significant prediction biomarker in the Kwak study and aided in the development of a sarcopenia
risk score, in combination with three additional biomarkers (Kwak et al., 2018). Unfortunately,
the scope of the present investigation did not result in the development of a sarcopenia risk score,
nor did the findings suggest one could be developed.
Other studies have identified correlational relationships with biomarkers and conditions
of muscle atrophy (Abbasi et al., 1998; Banerjee et al., 2011; Calvani et al., 2018; GonzalezCadavid et al., 1998; Ju & Chen, 2012; Roubenoff et al., 2003; Yarasheski et al., 2002), yet it can
be difficult to delineate which biomarkers are most influential to the models. Some of this
variability may be attributed to means for measuring biomarkers. For example, IGF-1 is more
readily measured in the serum, whereas myostatin is mainly expressed in skeletal muscle (Scharf
& Heineke, 2012) making muscle biopsy a more ideal means for measure. Given both
biomarkers were measured solely in serum for the present investigation, myostatin
concentrations may not be as valid when compared to skeletal muscle concentrations.
Model 2: Biomarkers and influential lifestyle factors. Inadequate nutrition and
decreased physical activity performance further emphasize age-dependent declines in muscle
mass (Gutmann & Hanzlíková, 1973; Sheffield-Moore & Urban, 2004). Therefore, an additional
regression model was examined taking into consideration the potential influence of dietary
protein intake and caloric expenditure from exercise-related physical activity. To-date, a
prediction model utilizing serum biomarkers and/or lifestyle factors related to sustaining muscle
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mass with age does not appear to be available. However, it is well known that physical activity
and dietary behaviors influence the healthy aging process (Södergren, 2013), contributing to
enhanced longevity (Gremeaux et al., 2012). Interesting, only sex and total dietary protein intake
were significant predictors of appendicular skeletal muscle mass for the current sample
population, accounting for 70.2% and 10.7% of model variability, respectively. Sex-specific
model analysis revealed total dietary protein intake significantly contributed to model variability
(21.2%) among males but did not among females (6.3%). Additionally, exercise-related activity
caloric expenditure did not significantly contribute to either sex-specific model. Although these
results are somewhat telling of potential relationships with lifestyle factors, as they relate to
appendicular skeletal muscle mass, much ambiguity remains. Further research is needed to
identify specific biomarkers and/or lifestyle factors indicative of increased risk for sarcopenia.

Relationship evaluations
Additional research hypotheses regarding biomarker relationships with age and
appendicular skeletal muscle mass were proposed for the present investigation. While
correlations with age for both biomarkers were consistent with the proposed hypotheses,
correlations with appendicular skeletal muscle mass were contradictory.
Serum myostatin and age. Prior studies have indicated myostatin concentration to
positively correlate with age, suggesting that as individuals get older, serum myostatin
concentration becomes greater leading to reduced lean mass (Schulte & Yarasheski, 2001; Szulc
et al., 2012; Yarasheski et al., 2002). Conversely, analyses in the present investigation suggest
myostatin has no association with age (Tables 9-11), regardless of sex. Specific to males, these
findings are in opposition to those of Szulc and colleagues (Szulc et al., 2012) in which serum
myostatin positively correlated with age among men aged 57 years and younger (r = .11, p < .05)
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and negatively correlated with age among men over 57 years of age (r = -.07, p < .05).
Unfortunately, comparison data examining correlation analyses with myostatin and age are
variable, making the generalizability of the results from the present investigation difficult to
interpret beyond that of converse findings to that of Szulc and colleagues (Szulc et al., 2012).
Greater emphasis on the relationship of myostatin with age has been placed on differences in
concentrations across age cohorts and is further discussed.
Cross-sectional results from the present investigation indicated non-significant
differences in myostatin concentration among middle-aged and older adults (Figure 3). The few
studies that have examined age-related differences in serum myostatin concentration (Lakshman
et al., 2009; Schulte & Yarasheski, 2001; Yarasheski et al., 2002) have indicated varying results.
Schulte and Yarasheski (2001) found older men and women (aged 60-75 years) to have
significantly greater serum myostatin concentrations than younger men and women (aged 19-35
years) (Schulte & Yarasheski, 2001), whereas Lakshman and colleagues (2009) found younger
men (aged 21-31 years) to have significantly higher myostatin concentrations than older (aged 171 years) men and no significant difference existing between young and old women (Lakshman
et al., 2009). Results from the present investigation contrast with the findings of Schulte and
Yarasheski (2001) given no significant differences were found between age cohorts. However,
when examining sex-specific results for the present investigation, some congruency is present.
Although men in the present investigation had relatively equivalent myostatin concentrations
across all age cohorts, men in the 60-69-year-old age group exhibited the highest concentrations,
which is similar to the findings of Schulte and Yarasheski (2001) and in stark contrast to the
findings of Lakshman and colleagues (2009). Looking specifically at women, the opposite is
true. Among females in the present investigation, non-significant differences were demonstrated
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for serum myostatin concentration across age cohorts. These results are like that of Lakshman
and colleagues (2001) and different from the results of Schulte and Yarasheski (2001).
Unfortunately, the age cohorts examined are not exactly the same among any of the prior studies,
nor with the present investigation. Utilizing middle-aged individuals as a comparison cohort is of
benefit in identifying trends for myostatin concentration over time, but further works are needed
to delineate the true relationships with myostatin and age.
Perhaps the most comparable data the present investigation provides is the trend for
serum myostatin concentration variability among middle-aged and older adults. While prior
investigations have examined differences in serum myostatin concentrations among varying age
cohorts (Schulte & Yarasheski, 2001; Yarasheski et al., 2002), the current investigation is the
first to examine serum myostatin concentrations among middle-aged older adults as opposed to
young (19-35 years) and older (60+ years) adults; thus, filling an age-gap need. Despite not
comparing middle-age and older adults to young adults in the present investigation, results were
similar to those of those of Yarasheski and colleagues (Schulte & Yarasheski, 2001; Yarasheski
et al., 2002) in that myostatin concentrations did vary across age cohorts; however, these
differences were variable, non-significant, and largely inconsistent. For example, in the present
investigation, the greatest serum myostatin concentrations were present among individuals aged
60-69 years and the lowest concentrations present among the middle-aged and the oldest (70+
years) adults for the total sample. In prior studies trends have identified serum myostatin
concentrations to be significantly greater with each progressing age bracket examined
(Yarasheski et al., 2002). That was not the case in the present investigation given concentrations
were lowest among one of the younger age cohorts (50-59-year-old group) and greatest among
the 60-69-year-old age group with another marginal decline between the 60-69-year-old age
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group and the 70+ year-old age group. Reasons for this could be attributed to the fact that prior
investigations had populations including frail individuals, whereas the present investigation had
apparently healthy individuals of mostly normal lean mass status.
Although, sex-specific differences were apparent in the present investigation. Namely,
males in the present investigation had significantly greater serum myostatin concentrations than
females (Table 6). Specific to males, older males (60-69 years) had serum myostatin
concentrations greater than those of their younger and older counterparts, although these
differences were not significant. Additionally, 60-69-year-old males had 27.3% greater
concentration than the 40-49-year old age groups and 32.9% greater concentration than the 5059-year-old group. These results are within the parameters observed by Yarasheski and
colleagues in which males 60-75 years of age had 22-40% greater myostatin concentration than
the young (20-35 year old) cohort (Yarasheski et al., 2002). In contrast to the Yarasheski study,
the present investigation grouped older males in a 60-69-year-old and 70+ year old cohort. In
doing so, identification of potential decade differences was made possible, whereas Yarasheski
and colleagues grouped individuals aged 60-75-years together, making it difficult to discern
potential differences. Although insignificant, analysis in the present investigation revealed males
aged 60-69 years had 19.4% greater myostatin concentration than males aged 70+ years. This
finding is incongruous with trends identified in previous literature, suggesting health status and
lifestyle factors of the present sample may be influential on myostatin concentration regulation.
Finally, non-significant differences in myostatin concentration across age decades were
also prominent among females. Contrary to the findings of Yarasheski et al. (2002) and Kim,
Cross, and Bamman (2005), older women in the current investigation did not exhibit greater
myostatin concentrations than their younger counterparts. The highest myostatin concentrations
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were present among females aged 40-49 years and the lowest concentrations among the 70+ year
old age group. Although myostatin concentration was slightly higher (0.9%) when examining
serum concentration differences between females aged 50-59 years and 60-69 years in the
current study, these value differentials were neither significant nor telling of identifiable trends
for females with progressing age. Given the understanding of trends for myostatin concentration
with age, these findings are opposite of the expected outcome and inconsistent with older women
exhibiting 32.5-42% greater myostatin concentration than their younger counterparts (Kim,
Cross, & Bamman, 2005; Yarasheski et al., 2002). While it is unknown the exact variables
specifically contributing to these differences, it may be plausible to speculate that lean mass
differences between samples in the current and prior investigations may play a role, given
females in the present investigation were not classified as frail nor sarcopenic.
Altogether, myostatin presents as a prominent biomarker for further investigation, as its
role, in relation to age, remains to be elucidated. Few studies are available examining myostatin
solely as it relates to age. Consequently, the disparity in the findings from the present
investigation, in combination with the disparity in findings for other investigations (Sharma et
al., 2015) makes it difficult to discern the true role myostatin may play in relation to age. Further
investigations should be conducted examining myostatin solely as it relates to age, both at the
blood and mRNA level given variability. This will help delineate ambiguities in methodological
variability (Sharma et al., 2015) as well as contribute to the development of normative ranges for
potential clinical use in human models.
Serum IGF-1 and age. Specific to IGF-1, it was hypothesized that serum concentrations
would inversely correlate with age, suggesting IGF-1 concentrations would be significantly
lower among older individuals, as compared to middle-aged adults. Cross-sectional data from
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prior studies indicate serum IGF-1 to be a significant negative correlate with age (Juul et al.,
1994), irrespective of sex (Hofmann et al., 2015; Juul et al., 1994; Lin et al., 2009; Rosario,
2010; Yamamoto et al., 1991). Consistent with findings from previous investigations, serum
IGF-1 concentration presented as a weak, but non-significant, negative correlate with age (r = .19, p = .06). Interestingly, when examining sex-specific correlates of IGF-1 with age, a
significant, moderate association was found among the females (r = -.39, p = .002), whereas
there was a negligible association for males (r = .01, p = .94). The variability in these
relationships could be due to the smaller male sample size and/or the significant differences in
lean tissue mass between males and females, which will be further discussed later.
In addition to serum concentration associations, cross-sectional exploration of trends for
IGF-1 concentration decrements with progressing age was also explored in the present
investigation. Early and continuing works indicate IGF-1 concentration progressively declines
throughout adulthood (Harris et al., 1997; Juul et al., 1994). Results from the present
investigation are not entirely consistent with these findings (Table 4) in that IGF-1
concentrations did not exhibit a continual progressive decline with increasing age; although,
there were significant differences between age cohorts. Consistent with previous studies the
youngest cohort in the current investigation (40-49 y/o) presented with the greatest average IGF1 concentration (61.1 ± 17.2 ng/mL), and a progressive decline was seen in the 50-59-year-old
(54.6 ± 14.4 ng/mL) and 60-69-year-old cohorts (46.4 ± 17.9 ng/mL); however, the 70+ year old
cohort had greater concentration values (52.5 ± 19.8 ng/mL) than that of their younger 60-69year-old counterparts. In addition, the magnitude of decline present among adults aged 60-69
years of age, as compared to their middle-aged counterparts (40-49 years and 50-59 years) was
consistent with the 10-31% decline exhibited in prior investigations (Benbassat et al., 1997;
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Brabant et al., 2003; Chanson et al., 2016; Lin et al., 2009; Rosario, 2010; Yamamoto et al.,
1991). Specifically, the 50-59-year-old age cohort had 10.7% lower concentration than that of
the 40-49-year-old cohort and the 60-69-year-old cohort had 15% lower concentration than that
of the 50-59-year-old cohort. Conversely, individuals in the present investigation, aged ≥ 70
years, exhibited IGF-1 concentrations 13.1% greater than their 60-69-year-old counterparts. This
is in stark contrast to the additional 3-30% decline in IGF-1 concentration traditionally exhibited
in comparing IGF-1 concentration among individuals aged ≥ 70 years to their younger 60-69year-old counterparts (Brabant et al., 2003; Chanson et al., 2016; Friedrich et al., 2008; Lin et al.,
2009; Rosario, 2010; Yamamoto et al., 1991). Possible reasons attributed to these results
comparisons may be due to the relatively higher dietary protein intake of the present cohort
and/or physical activity level, as lifestyle factors do influence IGF-1 regulation.
While results from this investigation are comparable to overarching results and trends for
IGF-1 decline with age, one limitation is the lack of congruency in actual values obtained for
concentration levels. Of the studies examined for premise of the present investigation, IGF-1
concentration ranged anywhere from 60-573 μg/L, depending on age cohort being examined and
the type of measures (serum vs. plasma; Table 4); values for the present investigation ranged
from 29.0-78.3 μg/L. Potential reasons for this large variability could be multi-factorial and
relate to anything from single measurement and within-subject variability to immunoassay
procedure limitations and lack of continuity in reference intervals throughout varying cohorts
(Chanson et al., 2016). Future investigations should aim to establish consistent reference ranges
across commercial assays to ensure adequate IGF-1 concentration comparison among large
sample populations.
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Serum myostatin and lean tissue mass measures. Given the catabolic role myostatin
plays in hormone signaling for protein synthesis and tissue growth, it was hypothesized the
serum myostatin concentrations would negatively correlate with appendicular skeletal muscle
mass in the present investigation; meaning, serum myostatin concentration would be greatest
among individuals with the lowest levels of lean tissues mass. Results from the present
investigation indicated the opposite as expected; serum myostatin was a weak, significant,
positive correlate with both total lean tissue mass and appendicular skeletal muscle mass (r =
0.21, p < .05). This is in contrast to studies investigating muscle wasting diseased states in
which serum myostatin concentrations were greatest among individuals with lower lean tissue
mass (Gonzalez-Cadavid et al., 1998; Ju & Chen, 2012). The difference in these findings, as
compared to that of the present investigation, could be due to the lack of skeletal muscle mass
decline exhibited among the cohort in the present investigation. For example, the conditions in
which Gonzalez-Cadavid and colleagues (1998) and Ju and Chen (2012) examined myostatin
relationships with skeletal muscle mass were different than that of the present investigation.
Specifically, Gonzalez-Cadavid and colleagues (1998) examined myostatin in relation to skeletal
muscle mass among men with muscle wasting as a result of HIV (Gonzalez-Cadavid et al., 1998)
and Ju and Chen (2012) examined relationships of myostatin among individuals with COPD and
muscle wasting (Ju & Chen, 2012). In both instances, it was found that myostatin had a
significantly moderate, negative association with skeletal muscle mass (Gonzalez-Cadavid et al.,
1998; Ju & Chen, 2012), which is opposite of what was displayed in the present investigation.
These differences, however, could be attributed to the fact that individuals in the present
investigation were free from HIV and did not present with any current or prior diagnoses of
conditions that would result in skeletal muscle wasting outside of natural declines.
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Interestingly, results from the present investigation are consistent with the recent work by
Arrieta and colleagues (2019) which indicate serum myostatin concentration is greater in more
fit and active older adults (Arrieta et al., 2019). It was also in this study that Arrieta and
colleagues (2019) identified their non-frail sample population to have significantly greater serum
myostatin concentrations than those individuals classified as frail, based on body composition
and functional measures (Arrieta et al., 2019). While the sample population was not classified as
frail or non-frail, results were consistent in myostatin concentration being elevated among age
groups in which lean tissue mass was preserved. Additionally, the sample population in the
present investigation was physically active, further supporting the findings of greater myostatin
concentration in active older adults. Unfortunately, this is the only study known to the
investigator in which it was found that results for myostatin were a positive correlate. These
results are opposite of what is expected, based on the function of myostatin; thus, speaking to the
potential sensitivity and variability of serum myostatin concentration among humans. Further
research is needed examining populations of all types (e.g. frail, non-frail, disease, non-diseased)
to better identify the true mitigating association serum myostatin may have with skeletal muscle
mass.
Serum IGF-1 and lean tissue mass measures. Understanding the anabolic role IGF-1
plays in hormone signaling, respective to protein synthesis and tissue growth, it was
hypothesized that serum IGF-1 concentration would positively correlate with appendicular
skeletal muscle mass. This suggested that greater IGF-1 concentrations would be present among
individuals with greater appendicular skeletal muscle mass, as compared to individuals with
lower appendicular skeletal muscle mass. Correlation results from the present investigation were
consistent with the proposed hypothesis; IGF-1 concentration was a significant positive correlate
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of moderate association with both total lean tissue mass (r = .36, p < .001) and appendicular
skeletal muscle mass (r = .35, p < .001). These results are congruous with results of Caregaro et
al. (2001), in that IGF-1 was a significant positive correlate with muscle mass (r = .66, p <.001)
(Caregaro et al., 2001). However, these results are also in contrast to the findings of Payette et al.
(2003), in which IGF-1 concentration did not correlate with body composition estimates
although IGF-1 served as a significant predictor in preservation of muscle mass over a
longitudinal period of time (Payette et al., 2003). Taken together, IGF-1 concentrations do not
appear to consistently correlate with anthropometric or tissue-specific metrics (Brugts et al.,
2008; Harris et al., 1997; Payette et al., 2003; Vestergaard et al., 2014) among middle-aged and
older population, like they do in younger in younger populations (<20 years) (Juul et al., 1994).
In summation, lower IGF-1 concentrations have been associated with lower levels of lean
mass (Harris et al., 1997), and higher IGF-1 concentrations indicative of smaller decrements of
lean mass loss with progressing age (Payette et al., 2003), suggesting a certain sarcopenia
protective effect of IGF-1 with age. While the results from the present investigation indicated
serum IGF-1 values well below that of those found in previous studies, they were somewhat
consistent with lean tissue mass declines in that that lowest levels of IGF-1 concentration were
present among individuals with lower lean tissue mass. Unfortunately, the present investigation
does not contain a sample of widely varying lean tissue mass measures, so results are not
generalizable to conditions of muscle wasting with age. Therefore, future studies are needed to
further delineate the relationship of IGF-1 with individuals of normal health status, but varying
levels of lean tissue mass, to include sarcopenic.
Lean tissue mass measures and age. Many physiological functions are maintained with
age, but subtle changes to most organ systems occur by the third and fourth decades of life (Boss
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& Seegmiller, 1981). Decrements are most commonly seen in organ systems where homeostatic
conditions are not maintained, such as skeletal muscle mass (Abrass, 1990). Among healthy
young adults, changes in skeletal muscle mass are not usually prominent if balance between
protein synthesis and degradation are maintained (Thomas, 2007). However, between ages 30-70
years, muscle mass declines at a rate of 2-3% per decade (Chodzko-Zajko et al., 2009), with
decline occurring in both sedentary and physically active aging adults (Thomas, 2007). The most
consistent declines in muscle mass often take place after 50 years of age, reaching upwards of 12% per year (Hughes, Frontera, Roubenoff, Evans, & Singh, 2002).
While the present investigation did not examine longitudinal changes in lean tissue mass
measures among the sample population, trends in muscle mass change were noticeable in crosssectional examination of age, per decade cohort. From a total sample perspective, there were no
significant differences in lean tissue mass measures between age cohorts; however, the lowest
average total lean tissue mass content was present among the 50-59-year-old age cohort. All
other cohorts were relatively equivocal in average total lean tissue mass. This was somewhat
expected given the most consistent lean mass declines often take place after 50 years of age
(Hughes et al., 2002). However, variability between decades in the present investigation were not
as expected. Given the 1-2% annual decline in lean mass after age 50 years (Hughes et al., 2002),
it was expected that the 60-69 year old age cohort would have upwards of a 9% lower lean tissue
mass status than that of the 50-59 year old age cohort and that this rate of lower lean tissue mass
would continue with each progressing decade. What was found was that the 50-59-year-old age
group had 7.1% less total lean tissue mass than that of the 40-49-year-old age group. With each
progressing decade, however, total lean tissue mass was greater. Individuals age 60-69 years had,
on average, 6.9% more total lean tissue mass than that of the 50-59-year-old age group.
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Similarly, the 70+ year old age group exhibited a greater average total lean tissue mass (1.0%)
than that of the 60-69-year-old age group.
While these results are inconsistent with previous literature (Hughes et al., 2002), they do
potentially speak to the demographic of the population in the present investigation. Potential
reasons for this could have been due to overall lifestyle characteristics of the participants.
Traditionally, dietary protein intake declines with progressing age, performance of physical
activity becomes less, and circulating levels of hormones (such as myostatin and IGF-1) become
dysregulated (Goldspink, 2012) either from onset of a diseased state (Gonzalez-Cadavid et al.,
1998; Ju & Chen, 2012) among the elderly or due to natural loss of muscle mass and function.
However, all individuals in the present investigation were healthy adults, free from chronic
disease. Additionally, many of the individuals were physically active and consumed more dietary
greater amounts of dietary protein, which may attribute to the preservation of total lean tissue
mass among the older cohorts in the present investigation. Unfortunately, due to the parameters
of the questionnaires used to estimate caloric expenditure from exercise-related physical activity
and assess dietary protein intake, it is difficult to discern if these differences are a result of more
active participation in resistance or aerobic exercise training or specifically due to optimal
nutrition.
Dietary protein intake
Dietary protein intake was not a primary outcome variable examined in the present
investigation, but was examined given the understanding that hypocaloric feeding and
decrements in protein intake are influential factors on age-dependent muscle mass alteration
(Sheffield-Moore & Urban, 2004). At present, the recommended dietary allowance (RDA) for
protein intake for adults, aged 18 years and older, is 0.8 g-1∙kg-1∙d-1 (Institute of Medicine, 2005);
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however, 10-30% of community-dwelling older adults do not meet this need (Appleton, 2016;
Berner, Becker, Wise, & Doi, 2013; Fulgoni, 2008; Smithers et al., 1998). Although the sample
in the present investigation examined middle-aged and older adults, results indicate average
dietary protein intake was above that of the RDA (0.95 ± 0.37 g-1∙kg-1∙d-1). Nevertheless, the
percentage of community-dwelling adults in the present investigation not consuming the RDA
(33%) is consistent with prior studies (Appleton, 2016; Berner et al., 2013; Fulgoni, 2008;
Smithers et al., 1998). Due to body composition changes and impaired nutrient absorption with
progressing age, the recommended quantity of protein needed for optimal absorption among
older adults ranges from 1.0-1.5 g-1∙kg-1∙d-1 (Houston et al., 2008; J. E. Kim, O'Connor, Sands,
Slebodnik, & Campbell, 2016; Paddon-Jones et al., 2015). In comparison, 40.4% of individuals
aged 60 years or older in the present investigation consumed the recommended amount of
protein for optimal absorption. This large percentage of individuals consuming within the
recommended limits for optimal absorption may attribute to the lack of significant difference in
appendicular skeletal muscle mass across age cohorts for the present sample.
Exercise-related activity energy expenditure
Skeletal muscle mass can be increasingly more challenging to maintain with progressing
age (Sheffield-Moore & Urban, 2004), but participation in regular exercise and physical activity
may mitigate these declines. Though results for the present investigation cannot be delineated for
activity modality (i.e., cardiovascular exercise or resistance training), the overall activity level of
the sample population suggests this sample to be active, based on average exercise-related
physical activity caloric expenditure values (total sample: 4182.9 ± 2647.1 kcal; females: 4282.6
± 2600.1 kcal; males: 3979.4 ± 2786.0 kcal). Sex-specific differences in total exercise-related
physical activity caloric expenditure was not present, but females expended 7.6% more calories
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than men, on average. Examination of physical activity level, relative to ACSM guidelines,
indicates the sample population does not meet minimum requirements. On average, the present
sample performed 2.33 hours of exercise-related physical activity, which is equivocal to
approximately 140 minutes. ACSM guidelines recommendations for individuals is to complete a
minimum of 150 minutes of moderate-intensity or 75 minutes of high-intensity exercise each
week (ACSM, 2017). The current sample did not meet the minimum recommendation; granted,
these guidelines are related to performance of cardiovascular activity, with additional guidelines
set forth for resistance training. Furthermore, given the parameters of the physical activity
questionnaire and the adapted metabolic equivalent values (Stewart et al., 2001), it is difficult to
discern what percentage of the total completed time was performed at a moderate and/or high
intensity. Similarly, it is difficult to discern if individuals were performing a regular weightlifting
and/or cardiovascular regimen. Future investigations interested in exploring exercise with aging
should aim to obtain exercise logs and/or perform detailed interview-style physical activity
questionnaires to ensure an accurate representation of caloric expenditure across all ages and
ability levels.
As mentioned, a notable limitation with the evaluation of energy expenditure from
exercise-related activities lies in the method in which these data were obtained for the current
study. The physical activity questionnaire used (CHAMPS) was designed for use among older
adults, not middle-aged adults. Consequently, data for the middle-aged adults may not be an
accurate representation of caloric expenditure from exercise-related physical activity due to the
adapted MET values used for algorithm calculations. Additionally, data were analyzed utilizing
all exercise-related activities, meaning the activity performed may not have been of moderate- or
high-intensity (e.g. leisure walking; playing golf riding in a cart; etc.); thus, there may not have
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been an imposed training, cardio protective, or muscle maintenance effect of the performed
activities. Finally, the questionnaire was designed to be completed via paper and pencil but was
completed online. The transition to using electronic completion resulted in some missing data
and inability to use all responses submitted.
Sarcopenia classification
The present investigation is novel in design given the proposition of a model to predict
appendicular skeletal muscle utilizing blood biomarkers. Skeletal muscle mass loss with age is of
clinical importance given the affiliated decrements in strength (Cruz-Jentoft et al., 2010;
Lauretani et al., 2003; Studenski et al., 2014) and functionality (Chodzko-Zajko et al., 2009;
Cruz-Jentoft et al., 2010; Studenski et al., 2014). And, while alteration in skeletal muscle mass is
a normative physiological aging process, a consistent means for monitoring this alteration is not
yet common practice.
Various working groups (Baumgartner et al., 1998; Chen et al., 2014; Cruz-Jentoft et al.,
2010; Fielding et al., 2011; Morley et al., 2011; Muscaritoli et al., 2010; Studenski et al., 2014)
have developed operational definitions for sarcopenia diagnosis (Table 3), but inconsistency in
criteria used to determine sarcopenic status yields inconclusive establishment of sarcopenia
classification. This is apparent when utilizing the criteria outlined in Table 3 to stratify the
sample population from the present investigation.
Throughout the data collection process, participants were classified as sarcopenic or nonsarcopenic based on ASMBMI values, as this is one of the primary outcome measures used by
FNIH to determine sarcopenia status (Studenski et al., 2014). However, as seen in Table 3
(literature review), measures used to delineate sarcopenia status widely vary. As such, data for
the present sample population are presented in Table 16, with total sample and sex-specific
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percentages indicated for participant sarcopenia characteristics based on working definitions of
sarcopenia. Based on the working definitions, anywhere from 0-30% of participants were
classified as sarcopenic. Perhaps the most telling of the classification criterion were those
parameters established by Cruz-Jentoft and colleagues (2010), where individuals were classified
as sarcopenic if they met low lean mass status and fell below normative baselines for one of the
functional measures. In this instance, only 6.6% of the sample population in the present
investigation were classified as sarcopenic, all of which were females. In comparison, 10.4% of
the sample was classified as sarcopenic under the most recently established sarcopenia
classification criteria (Studenski et al., 2014). Though the variability amongst these two
prominent sets of sarcopenia classification criteria (Cruz-Jentoft et al., 2010; Studenski et al.,
2014) is only 3.8%, it still demonstrates the overarching problem with clinical sarcopenia
diagnosis – lack of consistency. Thus, establishing a means for correlating serological changes
with physical and functional changes affiliated with sarcopenia warrant continued investigation.
In doing so, greater strides toward the creation of an all-encompassing risk score incorporating
similar to that of Kwak and colleagues (Kwak et al., 2018)
Limitations
A proposed limitation of the present investigation stemmed primarily from the lack of
generalizability. Participants were recruited and enrolled only if meeting inclusionary criteria.
Consequently, individuals with one or more co-morbid health conditions, having experienced
acute ailment or injury resulting in hospitalization, or individuals currently undergoing treatment
for cancer or autoimmune related disease were omitted. Given the potential for lean tissue mass
alteration among these omitted groups, data from the present investigation are most applicable to
healthy individuals. Examination of unhealthy, diseased populations may tell a different story
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with regarding to biomarker relationships and predictability of appendicular skeletal muscle
mass.
Following conduction of all analyses, sample size and the cross-sectional design of the
current investigation presented as potential limitations. While sample size distribution was
relatively equal among age groups, majority of the sample population was female, making it
difficult to have largely interpretable results for males. Lack of longitudinal examination of
individuals over an extended period of time provided for difficult data interpretation on trends
for biomarker and lean tissue mass measure fluctuations between age cohorts, per decade. Future
investigations should target greater male participant enrollment for and/or examine individuals
over extended periods of time to monitor changes in biomarker and lean tissue mass measures.
Additionally, it is understood that aging adaptations are person dependent, with many factors
largely attributed to hereditary and lifestyle factors (Chodzko-Zajko et al., 2009). Results from
the present investigation assist in identifying trends for all variables among decades, but it does
not tell the story of changes that occur throughout the lifespan, which is ultimately what would
be most advantageous in prediction muscle mass with age. Looking forward, it would be
beneficial to examine all variables among an entire sample over an extended period of time. This
will afford for the opportunity to take into consideration lifestyle adaptations and natural aging
processes, as compared to a snapshot of these changes via the present cross-sectional design.
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Table 16
Participant Characteristics Based on Sarcopenia Classification Working Definitions
Cutpoints

Female
(n = 68)

<7.26
<5.45
>2 SDs below mean in individuals aged 1839y in NHANES III cohort

13.2%

20.6%

0%

0%

0%

4-minute walking speed test
1. Low muscle mass (ALM/ht2)

<0.8 m/s
≤7.23 kg/m2

<0.8 m/s
≤5.67 kg/m2

N/A

N/A

N/A

13.2%

29.4%

23.6%

2. Low muscle strength (HGS)

<30 kg

<20 kg

2.6%

13.2%

8.5%

3. Low physical performance (gait speed)

<0.8 m/s

<0.8 m/s

2.6%

1.5%

1%

**Diagnosis based exhibiting criterion 1 and
(criterion 2 OR 3)
ALM/ht2

0%

10.3%

≤7.23 kg/m2

≤5.67 kg/m2

Gait speed

<1.0 m/s

<1.0 m/s

6-minute walking distance

<400 m

<400 m

<26 kg

Alternate: Grip strength adjusted for BMI
(GSMAXBMI)
Recommended: Appendicular lean body mass
adjusted for BMI (ALMBMI)

Classification Criteria

Men

Baumgartner et al., 1998
Muscaritoli et al., 2010
(ESPEN-SIG)

ASM/ht2
Low muscle mass: % muscle mass

Fielding et al., 2011
(IWGS)

Studenski et al., 2014
(FNIH)

Janssen et al., 2002

Total
Sample (N
= 106)
17.9%

Male
(n = 38)

Study (Organization)

Cruz-Jentoft et al., 2010
(EWGSOP)

Present Investigation

Recommended: Grip strength (GSMAX)

Alternate: ALM
Skeletal Muscle Index (SMI)

Women

6.6%

13.2%

29.4%

23.6%

2.6%

10.3%

7.5%

<16 kg

2.6%

5.9%

3.8%

<1.0

<0.56

2.6%

1.5%

1%

<0.789

<0.512

5.3%

13.2%

10.4%

0%

25%

16%

0%

0%

0%

<19.72 kg
<15.02 kg
Normal SMI: >1 SD above sex-specific mean
of young adult (18-39y; Sarcopenic SMI: ≥2
SDs below sex-specific mean of young adult
(18-39y)
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Note: Table 3 is adapted from Table 1 in Beaudart et al. (2014), and Table 3 in the present investigation, highlighting the primary
working definitions of sarcopenia classification with respective cutpoints. ESPEN-SIG = European Society for Clinical Nutrition and
Metabolism Special Interest Groups; ALM = appendicular lean mass; ASM = appendicular skeletal muscle mass; BMI = body mass
index; SMI = skeletal muscle index.

Finally, the present investigation proposed a heavy case for use of biomarkers in the
prediction of appendicular skeletal muscle mass as it relates to sarcopenia classification.
However, significant variability exists when aiming to classify individuals as sarcopenic
(Baumgartner et al., 1998; Chen et al., 2014; Cruz-Jentoft et al., 2010; Fielding et al., 2011;
Morley et al., 2011; Muscaritoli et al., 2010; Studenski et al., 2014); this held true for individuals
in the present investigation (Table 16). Consequently, results from this study became largely
exploratory, but did establish a framework for future studies. Moving forward, data collection
methods should be adapted to include both a detailed health history questionnaire as well as body
composition analysis as pre-screening measures. This will allow for a more representative
population of sarcopenic and non-sarcopenic individuals, as defined by FNIH (Studenski et al.,
2014), and yield more conclusive results on biomarker relationships with muscle mass among
middle-aged and older adults.
Conclusion
In conclusion, it was observed that serum myostatin and IGF-1 concentrations are not
significant predictors of appendicular skeletal muscle mass among middle-aged and older adults.
The experimental approach was cross-sectional in design and relied on prior investigations in
hypothesizing the use of such biomarkers as means for detecting muscle mass decline prior to
sarcopenia onset. Results were not in favor of the proposed model, but the limitations to study
parameters may have contributed to result variability. Therefore, future investigations aimed at
utilizing blood profiles for predicting skeletal muscle mass status should recruit a larger sample
of individuals and stratify individuals as sarcopenic and non-sarcopenic when making a claim for
meaningful relationships. At a minimum, results of the present investigation add to the
meaningful conversation regarding the need for a preventative medicine approach when it comes
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to sarcopenia diagnosis. Further evaluation of key relationships amid all sarcopenia-contributing
variables serves as a starting point, as there is still a large body of knowledge expressing serum
measure variability based on age and muscle mass status.
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Appendix A: Health History Questionnaire

Health History Questionnaire

Code:_______

Please answer the following questions as completely as possible.
Today’s Date: ____________
(1) PRESENT HEALTH STATUS
What is your date of birth?
What is your current age?
What is your gender? Male/Female
How do you assess your present overall health status?

 Excellent  Good

 Fair

 Poor
What has been the pattern of your overall health picture over the past few (3-5) years?
 Stable

 Improving

 Declining

Do you currently have a primary care physician?

 Yes

Do you currently participate in any cardiovascular exercise?

 No
 Yes

 No

Do you currently participate in any strengthening/strength training exercise?  Yes  No
What is your assessment of your present state of physical fitness?
 Poor

 Below Average

 Average

 Above Average

 Excellent

(2) PAST MEDICAL HISTORY
Did you have any unusual childhood illnesses that left you with either residual abnormalities
or health concerns for the future? (i.e. Polio with isolated weaknesses; Rheumatic Fever with
heart valve damage; etc.)
 Yes
 No
If yes, please
explain:______________________________________________________________
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As an adult, have you had a history of any of the following conditions? Check yes or no. If
yes, please explain.
Heart Disease

 Yes  No

Heart Attack

 Yes  No

Angina (Chest Pain)

 Yes  No

Peripheral Artery Disease

 Yes  No

Stroke

 Yes  No

High Cholesterol (>220)

 Yes  No

High Blood Pressure (>140/90)

 Yes  No

Diabetes

 Yes  No

Rheumatic Fever

 Yes  No

Aneurysm

 Yes  No

Kidney disease/Renal Complications

 Yes  No

Lung disease

 Yes  No

Emphysemia/COPD

 Yes  No

Lung Cancer

 Yes  No

Other Cancer

 Yes  No

Unusual infections

 Yes  No

Gastrointestinal issues

 Yes  No

Liver disease/complications

 Yes  No

Other Illnesses not listed above

 Yes  No

Do you have a history of neuromuscular or musculoskeletal disease or injury that prohibits
performance of daily tasks?
 Yes
 No
(If, yes, please explain below)
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Have you ever had any of the following conditions? Check yes or no. If yes, please explain.
Arthritis, rheumatism, or gout

 Yes  No

Any joint, bone, or muscle pain

 Yes  No

Any joint, bone, or muscle injury

 Yes  No

Any physical disability

 Yes  No

Have you been hospitalized for anything other than surgery, at any time, in the past year?
 Yes
 No
If yes, please explain:

Have you had any surgeries/surgical procedures in the past 5-10 years?  Yes
If yes, please indicate surgeries below:

 No

Have you had any of the following conditions within the last year? Check yes or no. If yes,
please explain.
Severe Illness (in the last year)

 Yes  No

Operations (in the last year)

 Yes  No

Broken bone/fracture (in the last year)

 Yes  No

Fallen (in the last year)

 Yes  No
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Have you experienced any of the symptoms indicated below? Check yes or no. If yes, please
explain.
Pain and/or discomfort in the chest, neck, jaw, or arms

 Yes  No

Shortness of breath at rest or with mild exertion

 Yes  No

Dizziness

 Yes  No

Ankle edema (swelling)

 Yes  No

Rapid or irregular beating heart

 Yes  No

Leg pain, cramping, or tightness during exercise

 Yes  No

Heart murmur

 Yes  No
 Yes  No

Fatigue or shortness of breath during the day
 Yes  No

Do you smoke?

 Yes

Have you gained or lost weight in the past year?
If yes, which did you experience:

 Quit; date: _______
 No

 Weight Loss, amount: ____  Weight Gain,

amount: ____

Do you have a history of allergies?

 Yes

 No

Drug allergies (If yes, please explain)?

 Yes

 No

Food allergies (If yes, please explain)?

 Yes

 No

(3) FAMILY HISTORY
Father

Mother

Siblings

Is your father living?

Is your mother living?

Are any sibling(s) deceased?

 Yes

 Yes

 Yes

 No

 No

 No

How old is he (or age at

How old is she (or age at

How old are they (or age at

death)?

death)?

death)?

Does/did your father have
any of the following medical
problems?

Does/did your mother have
any of the following medical
problems?

Does/did your sibling(s) have
any of the following medical
problems?

 Heart Disease

 Heart Disease

 Heart Disease
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 Diabetes

 Diabetes

 Diabetes

 Lung

 Lung

 Lung

Disease/Emphysema/COPD

Disease/Emphysema/COPD

Disease/Emphysema/COPD

 Cancer

 Cancer

 Cancer

 High Blood Pressure

 High Blood Pressure

 High Blood Pressure

 High Cholesterol

 High Cholesterol

 High Cholesterol

 Serious Infections

 Serious Infections

 Serious Infections

 Gastrointestinal Issues

 Gastrointestinal Issues

 Gastrointestinal Issues

 Liver

 Liver

 Liver

Disease/Complication

Disease/Complication

Disease/Complication

 Kidney

 Kidney

 Kidney

Disease/Complication

Disease/Complication

Disease/Complication

Please provide details for the
conditions indicated above:

Please provide details for the
conditions indicated above:

Please provide details for the
conditions indicated above:

(4) PLEASE INDICATE ALL MEDICATIONS AND NUTRITION SUPPLEMENTS
(PRESCRIPTION OR OVER-THE-COUNTER) YOU ARE CURRENTLY TAKING OR
USE.
Med./Supp.

Reason Prescribed

When do you take this medication/supplement?
(check all that apply)

_____  Morning  Mid-Day  Evening  Bedtime
_____  Morning  Mid-Day  Evening  Bedtime
_____  Morning  Mid-Day  Evening  Bedtime
_____  Morning  Mid-Day  Evening  Bedtime
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_____  Morning  Mid-Day  Evening  Bedtime
_____  Morning  Mid-Day  Evening  Bedtime
_____  Morning  Mid-Day  Evening  Bedtime
___________

 Morning  Mid-Day  Evening  Bedtime
 Morning  Mid-Day  Evening  Bedtime
 Morning  Mid-Day  Evening  Bedtime

Thank you for completing this Health History Questionnaire. Please
return to Ashley Binns, binns@email.uark.edu

125

Appendix B: Informed Consent

INFORMED CONSENT
Title: Serum Myostatin and IGF-1 as Biomarkers of Sarcopenia: A Proof-of-Concept
Design
Researchers:
Ashley Binns, M.S.
Michelle Gray, Ph.D.
University of Arkansas
Department of Health, Human Performance,
and Recreation - HPER 321-E
479-575-2975

Administrative Contact Person:
Iroshi Windwalker
Compliance Coordinator
109 MLKG
(479) 575-2208
irb@uark.edu

Purpose: The purpose of this study is to provide evidence supporting the use of blood measures
in predicting muscle mass among middle-aged (40-59 years) and older adults (≥60 years).
Inclusion Criteria: You must be at least 40 years of age, free from unstable or unmanaged
cardiovascular disease, hypertension, or diabetes; no current renal (kidney) or hepatic (liver)
abnormalities or diseases; no known cognitive impairment; and no neuromuscular or
musculoskeletal disease or injury prohibiting participation in functional task performance or
activities of daily living (ADLs; bathing, grooming, dressing, eating, toileting,
ambulating/transferring).
Description: All testing will be completed within the Exercise Science Research Center and
Annex (HPER 321 & HPER 323). Before any physical assessment is conducted, a detailed health
history questionnaire will be completed to provide relevant information regarding current state of
health and ensure you are not at increased risk of injury when performing the physical
measurements. You will be asked to complete the Mini-Mental State Examination (MMSE). If
the MMSE score is less than 17 (out of 30), additional testing will not be performed. Further, you
will complete a 24-hour diet record and the CHAMPS physical activity assessment
questionnaire; these will be used to assess baseline nutrient status and physical activity level.
Demographic information, including body weight, height, muscle mass, and fat mass will
be determined before physical fitness assessments are completed. Body weight will be measured
using a physician’s balance scale and height assessed using a standing stadiometer. Fat and Fatfree mass, as well as bone mineral density, will be measured with a dual-energy x-ray
absorptiometry (DXA) scanner. Following the DXA scan, blood draw and functional task
performance parameters (handgrip strength and walking speed) will be assessed. Details
regarding each of the assessments are indicated below:
Venous blood draw. Each participant will have a maximum of three vials (18 mL) of venous
blood taken upon reporting to the Exercise Science Research Center for their testing
appointment. Blood draws will be performed following a 12-hour overnight fast. All blood
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samples will be used to assess serum myostatin and IGF-1 (blood biomarkers) using ELISA
assay kits. The blood sampling procedure (i.e., venipuncture) and subsequent blood analysis was
approved by the Institutional Biosafety Committee (IBC protocol #13021) on February 14, 2013
and has an expiration date of February 13, 2019.
CHAMPS activities questionnaire for older adults will be completed by all participants and
used to evaluate physical activity levels among adults in metabolic equivalents (METS). This 41item paper and pencil questionnaire will be completed prior to arrival for testing via electronic
submission (e.g., Qualtrics). Should electronic submission not be feasible, participants will
complete the CHAMPS questionnaire upon arrival for their testing appointment.
Handgrip strength will be assessed using the Takei dynamometer. You will grip the
dynamometer in your hand and grip it as forcefully as possible; both hands will be tested three
times each with one-minute rest between trials.
The 20-meter walk will measure walking speed and require you to walk a total of 20-meters at
two different speeds (habitual walking speed and as quickly and safely as possible). You will be
asked to complete two trials at each speed with 90-120 seconds rest between trials.
To establish baseline nutrient status, individuals will complete a three-day dietary recall prior
to study participation utilizing the attached dietary record sheet. Macronutrient intake will be
analyzed utilizing the Nutritionist Pro (Axxya Systems, 2007). A 24-hour dietary record will also
be kept for the day preceding the testing appointment to take into account any influential factors
on biomarker presence and nutrient intake status. All analysis procedures will be the same as for
the three-day dietary recall.
Potential Risks: The risks involved in this particular project, although minimal, include
performance of various functional fitness parameters. When performing any type of exercise or
unfamiliar functional task, there is the possibility that participants will experience muscle
soreness the next day and for possibly 36-48 hours following the testing session.
Risks associated with the use of the DXA machine include the following: exposure to a small
amount of ionizing radiation. The amount received during a DXA test is about the same as four
(4) days of normal background radiation in Northwest Arkansas. As a result of all of the
aforementioned risks, medical clearance will be provided from participant physician prior to any
testing taking place.
Venipuncture may result in slight bruising, infection, soreness at the site of the blood
draw, and/or feeling of lightheadedness/fainting. These risks will be minimized using a standard
operating procedure previously approved by the Institutional Biosafety Committee (IBC protocol
#13021) and only enrolling participants that are otherwise healthy. Blood draws will only be
performed by those trained in the procedure. Universal precautions (PPE) will be utilized to
minimize any change of infection. The participants will be in a semi-reclined position during the
blood draw (minimizing any injury should they feel lightheaded).
Benefits: Participation in this study will allow you the opportunity to know where you stand
under all testing conditions. Additionally, it will afford all participants the opportunity to become
familiarized with various functional and cognitive assessments. Upon study completion,
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individuals will receive printed reports with their results. Per participant request, information can
also be made available to physicians. Generalized study results will be provided to all
participants so they are made aware of the outcomes of the study and all variables measured.
Confidentiality: You will be assigned a code number at random. The randomly assigned code
numbers will be used on all data collection sheets and for all analyses. Due to incremental
measures, a master file containing only participant names and their respective code numbers will
be kept on file until all study parameters have been completed. All data will be stored in a
locking filing cabinet in the primary investigator’s office or the Exercise Science Research
Center. Upon completion of all assessments, the master file with names and code numbers will
be destroyed (deleted from the PI’s computer). All information collected will be kept
confidential to the extent allowed by law and University policy. Only those directly involved in
the research project will have access to the data.
Right to withdraw: Your involvement in this research study is completely voluntary, and you
may discontinue your participation in the study at any time without penalty.
Questions Regarding the Study: If you have any questions about the research study you are
encouraged to ask the researcher; the phone number is at the top of this form. You will be given
a copy of this signed and dated consent form to keep, upon request.
Participant: I, ________________________________, have read the description and
information above. Each of these items has been read and explained to me by the investigator.
The investigator has answered all of my questions regarding the study, and I believe I understand
what is involved. My signature below indicates that I freely agree to participate in this
experimental study and that I have a received a copy of this agreement from the investigator.
Signature: ___________________________

Date: _________________
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Appendix C: Community Health Activities Model Program for Seniors (CHAMPS)
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Appendix D: Pre-testing Guidelines
PRE-TESTING GUIDELINES

Due to nature of the serological measures and fitness assessments being conducted in your
upcoming pre-testing session, it is important for some aspects of the study to be as controlled as
possible. Below are some guidelines that are important to follow prior to your upcoming testing
session. Please read through the list below and do your very best to follow as accurately as
possible.
1 Get a restful night’s sleep.
2. Refrain from consuming any food or beverages 12 hours prior to your testing appointment
time.
Example: if you have a 6am appointment, do not consume any food or beverage (other
than water) after 6pm the night before.
3. Refrain from consuming caffeine and/or alcohol at least 12 hours prior to your testing
appointment. Consumption of water the morning of your appointment is recommended.
4. Refrain from performing any exercise (especially strenuous) 24 hours prior to each testing
session.
e.g. cardio (running, rowing, walking, elliptical, bike, swimming, jump rope, spin, group
exercise, etc.); strength training (weights, weight machines, body weight exercises, group
exercise, etc.)
5. Maintain a regular eating pattern and focus on hydration the day prior to your testing session.
You will be asked to provide a 24-hour dietary recall upon arriving for your appointment. Please
use the template included in the Dietary Record Food Instructions (see next pages).
6. Feel free to bring a water bottle, snack, and light reading materials to each testing session.
There is a possibility you will have brief waiting periods in between assessments
depending on the number of people scheduled to come in at any given time.
Should you have any questions regarding any of the above information, feel free to contact me
via e-mail (binns@email.uark.edu) or phone at any time.
Thank you,
Ashley
Ashley Binns, M.S.
University of Arkansas
Department of Health, Human Performance, and Recreation
binns@email.uark.edu
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Appendix E: 24-hour Dietary Record and Instructions

DIETARY FOOD RECORD INSTRUCTIONS
•

ALL foods and beverages (INCLUDING WATER) that are consumed should be recorded.

•

Be very specific in your description of the type, the preparation method, and the amount of
each food/beverage you consume.

•

Use the label on foods to help you determine portion sizes.

•

Save labels from packages and return them with your food record forms (this will greatly
assist and enhance our analysis of your true nutrient intake).

•

Use nutrient descriptors (e.g., low-fat, fat-free, light, reduced calorie, etc.) and brand names
(e.g., Kraft, Nabisco, Planters, etc.) to describe foods.

•

Record food/beverage consumption after each meal/snack instead of waiting until the end of
the day.

MEATS/CHEESES
Description: Include description of the type, cut, and preparation method.
Portion Sizes:
List cooked (not raw) amounts of meats.
Determine amounts by weighing when possible.
Three ounces of cooked meat is equivalent to approximately a deck of cards or the palm
of your hand.
*Listed below are examples of how to document foods
3oz. Skinless, boneless, chicken breast-roasted
3oz. Ground beef round-fried
3oz. Deli turkey breast slices
3oz. Atlantic cod-baked
3oz. Sirloin steak-grilled
1/2 cup cubed beef stew meat
1 slice ham, 3" x 4" x 1/4"
1 oz colby cheese
1 piece cheddar cheese, 3" x 2" x 1"

139

STARCH/BREAD
(CEREALS, BREADS, PASTAS, RICES, BEANS)
Description: Include a complete description of the starch/bread including preparation method
and brand name if applicable.
Portion Sizes:
List cooked (not raw) amounts of starch/bread products.
Generally, a measuring cup will suffice for cereals, rices, pastas, and beans.
½ cup brown rice (Uncle Bens)
2 slices rye bread-toasted
2 cups spaghetti noodles-boiled
1½ cups dry cereal (Cheerios)
1 cup oatmeal (Quaker Oats)-microwaved
8 animal crackers
Blueberry muffin, small
½ cup canned baked beans
1 corn tortilla, 6" across
FRUITS/VEGETABLES
Description: Include description of fruit/vegetable and whether it was fresh, frozen, or canned.
Include preparation method (e.g., steamed, fried, etc.)
Portion Sizes:
For whole pieces of fruit or vegetables, you may use small, medium, or large.
For many fruits/vegetables, cups may be used also.
1 medium Granny Smith apple
½ of a large tomato-fresh
5 small strawberries-fresh
½ cup canned pineapple-canned in water
1 cup frozen peas-steamed
¾ cup frozen mixed vegetables
3 spears steamed broccoli
2 medium raw carrots
COMBINATION DISHES
For standard mixed dishes, it is generally acceptable to list the type of dish without trying to list
the ingredients separately. If the food is modified (e.g., low-fat), indicate this and try to describe
how the food was modified. Provide enough detail to explain the composition of the dish. For
tossed salad, list the individual ingredients paying careful attention to salad dressings and other
caloric-dense toppings (bacon bits, cheese, ham, chopped egg, etc.).
1 cup bean chili w/o meat
3 slices thin crust large cheese pizza with pepperoni-frozen
½ cup potato salad
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1 cup tuna casserole
1 cup macaroni and cheese (Kraft)
1 slice angel food cake
2 cups tossed salad
2 cups lettuce greens
3 slices cucumber
3 slices tomato
1 T shredded cheddar cheese
1 T shredded carrots
2 T fat-free Italian dressing
BEVERAGES/FLUIDS
Description: Include ALL BEVERAGES INCLUDING WATER complete description of the
beverage
Portion Sizes: Use fluid ounces, liters, cups, or tablespoons.
6 oz regular coffee, brewed
12 oz Diet Pepsi
1 cup 2% milk
16 oz unsweetened iced tea
4 oz red table wine
6 oz orange juice (from concentrate)
2 T light olive oil
MISCELLANEOUS
Remember to list all condiments and additions to foods and beverages, such as cream, sugar,
butter, jelly, lemon, salad dressing, artificial sweeteners, catsup, etc.
3 T low-fat french salad dressing
2 tsp black raspberry jam
1 packet Sweet'n Low
1 T cream (half and half)
2 tsp margarine spread (Country Crock)
3 T fat-free ranch salad dressing (Kraft)
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Day of Week/Date:

Time

______

Name:

FOOD/BEVERAGE DESCRIPTION

Total kcal
AMOUNT (from
label)

Comments:
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Appendix F: Mini-Mental State Examination (MMSE)
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Appendix G: IRB Approval Document
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Appendix H: GDF-8/Myostatin ELISA Assay Procedures
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Appendix I: IGF-1 ELISA Assay Procedures
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Appendix J: Gait Speed Diagram
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Appendix K: Data Collection Sheet

Data Collection Sheet
Informed Consent

Complete

HHQ Complete

24-hour Dietary Recall Complete

Attached list of medications? Yes
Any ‘red flags’?
Yes

No
No

MMSE Score:

/30

If yes, please indicate:______________________________________________________

CHAMPS

Complete

DXA Complete
date of birth (xx/xx/xxxx): __ / __ /______
height (cm):______

height (in)= height in cm / 2.54: _______

weight (kg):_______

weight (lbs)= wt in kg x 2.2:_______

Venipuncture Complete
Time completed:
Earliest spin:
Latest spin:

10-Meter Walk
Trial 1
Habitual Walking Speed, time (sec)
Quick, Safe Walking Speed, time (sec)

Rest
90-120 seconds
90-120 seconds

Trial 2

Handgrip Dynamometer
*be sure to time the rest periods in between each hand; circle the highest value per hand
Trial 1
Right hand
Left hand

Rest
60 seconds
60 seconds

Trial 2

Rest
60 seconds
60 seconds

Trial 3
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